```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:53:32 ON 27 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 AUG 2005  HIGHEST RN 861902-61-6
DICTIONARY FILE UPDATES:  26 AUG 2005  HIGHEST RN 861902-61-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que sta l2
L1              STR
```




```
G3—C—G3        O—Ak        C—G3
18 @19 20      @21 22      @23 24

VAR G1=OH/8/10
VAR G2=CH2/16/19
VAR G3=OH/AK/21
VAR G4=ME/23
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  24
```

STEREO ATTRIBUTES: NONE
L2 3458 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 690836 ITERATIONS 3458 ANSWERS
SEARCH TIME: 00.00.13

=> d ide l11 tot

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 106797-53-9 REGISTRY
ED Entered STN: 21 Feb 1987
CN 1-Propanone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-[4-(2-Hydroxyethoxy)phenyl]-2-hydroxy-2-methyl-1-propanone
CN 2-Hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone
CN 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone
CN 4-(2-Hydroxyethoxy)phenyl 2-hydroxy-2-propyl ketone
CN Darocur 2595
CN Darocur 2959
CN Irgacure 2959
CN ZLI 2959
FS 3D CONCORD
MF C12 H16 O4
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM,
PIRA, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

341 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
342 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ide l14 tot

L14 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 601468-78-4 REGISTRY
ED Entered STN: 09 Oct 2003
CN Hyaluronic acid, ester with 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-
methyl-1-propanone, phenylmethyl ester, sodium salt (9CI) (CA INDEX
NAME)
MF C12 H16 O4 . x C7 H8 O . x Na . x Unspecified
PCT Manual registration, Polyester, Polyester formed
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Search done by Noble Jarrell

CM 1

CRN 106797-53-9
CMF C12 H16 O4



CM 2

CRN 9004-61-9
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 3

CRN 100-51-6
CMF C7 H8 O



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 601468-77-3 REGISTRY
ED Entered STN: 09 Oct 2003
CN **Hyaluronic acid, ester with 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone, sodium salt (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **Hyaluronic acid 2-hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone ester sodium salt**
MF **C12 H16 O4 . x Na . x Unspecified**
PCT Manual registration, Polyester, Polyester formed
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 106797-53-9
CMF C12 H16 O4



```
     CM   2

     CRN  9004-61-9
     CMF  Unspecified
     CCI  PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d his full

     (FILE 'HOME' ENTERED AT 13:39:17 ON 27 AUG 2005)
               D SAV

     FILE 'REGISTRY' ENTERED AT 13:39:55 ON 27 AUG 2005
               ACT KRI472F0/A
              ---------
L1             STR
L2          3458 SEA SSS FUL L1
              ---------

     FILE 'HCAPLUS' ENTERED AT 13:41:07 ON 27 AUG 2005
L3             1 SEA ABB=ON  PLU=ON  US2005119219/PN OR (US2004-507472# OR
                 WO2003-EP2538#)/AP,PRN

     FILE 'REGISTRY' ENTERED AT 13:41:13 ON 27 AUG 2005

     FILE 'HCAPLUS' ENTERED AT 13:41:13 ON 27 AUG 2005
L4             TRA L3 1- RN :         3 TERMS

     FILE 'REGISTRY' ENTERED AT 13:41:14 ON 27 AUG 2005
L5             3 SEA ABB=ON  PLU=ON  L4
L6             0 SEA ABB=ON  PLU=ON  L5 AND L2
L7          1841 SEA ABB=ON  PLU=ON  C12H16O4 AND 46.150.18/RID
L8            49 SEA ABB=ON  PLU=ON  L7 AND 4 (1A)2(1A)HYDROXYETHOXY(1A)PHENYL
L9               QUE ABB=ON  PLU=ON  (PMS OR MAN OR IDS)/CI OR UNSPECIFIED OR
                 COMPD OR COMPOUND OR (D OR T)/ELS
L10            7 SEA ABB=ON  PLU=ON  L8 NOT L9
L11            1 SEA ABB=ON  PLU=ON  106797-53-9/BI AND L10
L12         1403 SEA ABB=ON  PLU=ON  (CHLAMHYALURON? OR HYALURON?)(W)ACID? OR
                 DUROLANE OR GENZYME OR HYALOBARRIER OR HYALOFILL OR HYALURON###
                  OR HYLAN OR HYLARTIL# OR LURONIT# OR MUCOITIN# OR SEPRACOAT
                 OR SOFAST OR SYNVISC
L13            0 SEA ABB=ON  PLU=ON  L12 AND (L11 OR L2)
L14            2 SEA ABB=ON  PLU=ON  L12 AND L8

     FILE 'HCAPLUS' ENTERED AT 13:51:50 ON 27 AUG 2005
L15            1 SEA ABB=ON  PLU=ON  L14
L16        17420 SEA ABB=ON  PLU=ON  L12
L17        18267 SEA ABB=ON  PLU=ON  (CHLAMHYALURON? OR HYALURON?)(W)ACID? OR
                 DUROLANE OR GENZYME OR HYALOBARRIER OR HYALOFILL OR HYALURON###
                  OR HYLAN OR HYLARTIL# OR LURONIT# OR MUCOITIN# OR SEPRACOAT
                 OR SOFAST OR SYNVISC
                 E HYALUR/CT
                 E E7+ALL
                 E E2+ALL
L18        12288 SEA ABB=ON  PLU=ON  HYALURONIC ACID/CT
L19         4611 SEA ABB=ON  PLU=ON  (L11 OR L2)

     FILE 'HCAPLUS' ENTERED AT 13:54:22 ON 27 AUG 2005
L20           24 SEA ABB=ON  PLU=ON  (HYDROXYETHOXY OR HYDROXY (1A)ETHOXY)(1A)PH
                 ENYL (5A)HYDROXY (1A)(METHYLPROPANONE OR METHYL(1A)PROPANONE)
L21           27 SEA ABB=ON  PLU=ON  (HYDROXYETHOXY OR HYDROXY (1A)ETHOXY)(1A)PH
```

```
                ENYL (5A)HYDROXY (1A)(PROPYLKETONE OR PROPYL(1A)KETONE)
L22          5005 SEA ABB=ON  PLU=ON  DARCUR? OR IRGACURE? OR ZLI2959 OR
                ZLI(1A)2959
L23            14 SEA ABB=ON  PLU=ON  (L19 OR L20 OR L21 OR L22) AND (L16 OR L17
                OR L18)
                E BELLINI D/AU
L24            20 SEA ABB=ON  PLU=ON  ("BELLINI D"/AU OR "BELLINI DAVIDE"/AU)
                E ZANELLATO A/AU
L25            13 SEA ABB=ON  PLU=ON  ("ZANELLATO ANNA"/AU OR "ZANELLATO ANNA M
                C"/AU OR "ZANELLATO ANNA MARIA"/AU OR "ZANELLATO ANNA MARIA
                C"/AU OR "ZANELLATO ANNA MARIA CECILIA"/AU)
                E ZANELLATO M/AU
                E FIDIA/CS,PA
L26           619 SEA ABB=ON  PLU=ON  FIDIA/CS,PA
L27             0 SEA ABB=ON  PLU=ON  L23 AND (L24 OR L25 OR L26)
L28               QUE ABB=ON  PLU=ON  PY<=2000 OR AY<=2000 OR PRY<=2000 OR
                PD<20020312 OR AD<20020312 OR PRD<20020312
L29             8 SEA ABB=ON  PLU=ON  L23 AND L28
L30            14 SEA ABB=ON  PLU=ON  (L23 OR L29)
                D SCA
L31           661 SEA ABB=ON  PLU=ON  (L16 OR L17 OR L18) (L) ESTER?
L32             1 SEA ABB=ON  PLU=ON  L31 AND PROPIOPHENONE?
L33             3 SEA ABB=ON  PLU=ON  L31 AND ?PHENONE?
L34             2 SEA ABB=ON  PLU=ON  L33 NOT L32

     FILE 'REGISTRY' ENTERED AT 14:06:23 ON 27 AUG 2005
L35             1 SEA ABB=ON  PLU=ON  131-57-7

     FILE 'HCAOLD' ENTERED AT 14:07:51 ON 27 AUG 2005
L36             0 SEA ABB=ON  PLU=ON  L14
L37           412 SEA ABB=ON  PLU=ON  L2
L38             0 SEA ABB=ON  PLU=ON  L11
L39             0 SEA ABB=ON  PLU=ON  L12
L40           557 SEA ABB=ON  PLU=ON  (CHLAMHYALURON? OR HYALURON?)(W)ACID? OR
                DUROLANE OR GENZYME OR HYALOBARRIER OR HYALOFILL OR HYALURON###
                 OR HYLAN OR HYLARTIL# OR LURONIT# OR MUCOITIN# OR SEPRACOAT
                OR SOFAST OR SYNVISC
L41             0 SEA ABB=ON  PLU=ON  L37 AND L40

     FILE 'HCAPLUS' ENTERED AT 14:09:22 ON 27 AUG 2005
L42             1 SEA ABB=ON  PLU=ON  (L15 OR L32)

=> b hcap

FILE 'HCAPLUS' ENTERED AT 14:09:48 ON 27 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Aug 2005  VOL 143 ISS 10
FILE LAST UPDATED: 26 Aug 2005  (20050826/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
```

substance identification.

=> d all fhitstr l42 tot

L42 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:737790 HCAPLUS
DN 139:262427
ED Entered STN: 19 Sep 2003
TI **Ester** derivatives of **hyaluronic acid**, preparation, hydrogel materials by photocuring, and biomedical use
IN Bellini, Davide; Zanellato, Anna Maria
PA Fidia Advanced Biopolymers S.R.L., Italy
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C08B037-08
ICS C08J003-28; C08J003-075
CC 44-5 (Industrial Carbohydrates)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003076475	A1	20030918	WO 2003-EP2538	20030312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478655	AA	20030918	CA 2003-2478655	20030312
EP 1519962	A1	20050406	EP 2003-743875	20030312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119219	A1	20050602	US 2003-507472	20030312
PRAI IT 2002-PD64	A	20020312		
WO 2003-EP2538	W	20030312		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003076475	ICM	C08B037-08
	ICS	C08J003-28; C08J003-075
WO 2003076475	ECLA	A61L027/20+C08L5/08; A61L029/04D+C08L5/08; A61L031/04D+C08L5/08; C08B037/00P2F
US 2005119219	NCL	514/054.000

OS MARPAT 139:262427
AB The **hyaluronic acid ester** derivs., have carboxylic groups are partially **esterified** with hydroxy groups of **propiophenone** derivs. Thus, 6.21 g tetrabutylammonium salt of **hyaluronic acid**, mol. weight 180,000 Da (10 meq.) are solubilized in 248 mL DMSO at room temperature, 2 g 2-hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone (HHMP) bromide (7 meq.) are added, the solution is maintained at 37° for 48 h, 2.5% NaCl solution is added and the mixture is poured under stirring into 750 mL acetone, precipitating, filtering and washing three times with 100 mL acetone:water 5:1, three times with 100 mL acetone, and lastly vacuum-drying 24 h at 30° gave 5.3 g HHMP **ester** product.
ST **hyaluronic acid ester** prepn photocuring hydrogel biol use
IT Drug delivery systems
(controlled-release; **hyaluronic acid esters** photocured for hydrogels for)

IT Cell proliferation
(fibroblast, scaffolds; **hyaluronic acid esters** photocured for hydrogels for)
IT Medical goods
(**hyaluronic acid esters** photocured for hydrogels for)
IT Drug delivery systems
(hydrogels; **hyaluronic acid esters** photocured for hydrogels for)
IT Fibroblast
(proliferation, scaffolds; **hyaluronic acid esters** photocured for hydrogels for)
IT 124-22-1DP, Dodecylamine, amide with **hyaluronic acid esters** **601468-77-3DP**, amide with dodecylamine
601468-77-3P, **Hyaluronic acid**
2-hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone **ester** sodium salt **601468-78-4P**
RL: BUU (Biological use, unclassified); IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**hyaluronic acid esters** photocured for hydrogels)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aeschlimann; WO 0016818 A 2000 HCAPLUS
(2) Fidia Advanced Biopolymers Srl; WO 9637519 A 1996 HCAPLUS
(3) Hercules Incorporated; EP 0749982 A 1996 HCAPLUS
(4) Nguyen, K; BIOMATERIALS 2002, V23(22), P4307 HCAPLUS
(5) Seikagaku Corporation; WO 9718244 A 1997 HCAPLUS
(6) Waki; US 6031017 A 2000 HCAPLUS
IT **601468-77-3DP**, amide with dodecylamine
RL: BUU (Biological use, unclassified); IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**hyaluronic acid esters** photocured for hydrogels)
RN 601468-77-3 HCAPLUS
CN Hyaluronic acid, ester with 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone, sodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 106797-53-9
CMF C12 H16 O4



CM 2

CRN 9004-61-9
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d all hitstr l30 tot

L30 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:471920 HCAPLUS
DN 143:13333
ED Entered STN: 03 Jun 2005
TI Excipients in drug delivery vehicles for depot gels
IN Chen, Guohua; Priebe, David T.
PA Alza Corporation, USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-14
ICS A61F013-00
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005048989	A1	20050602	WO 2004-US37606	20041112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-519972P	P	20031114
US 2004-985116	A	20041110

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005048989	ICM	A61K009-14
	ICS	A61F013-00
WO 2005048989	ECLA	A61K009/00M4; A61K047/34

AB Injectable depot gel compns. and kits that provide an excipient for modulating a release rate and stabilizing beneficial agents are provided. The gel compns. comprise biodegradable, bioerodible polymers and water-immiscible solvents in amts. effective to plasticize the polymers and form gels with the polymers. Suitable excipients include pH modifiers, reducing agents, and antioxidants. A gel composition was prepared containing glycolide-lactide copolymer.

ST drug delivery vehicle depot gel
IT Antioxidants
(excipients in drug delivery vehicles for depot gels)
IT Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(excipients in drug delivery vehicles for depot gels)
IT Polyanhydrides
Polycarbonates, biological studies
Polyesters, biological studies
Polyoxymethylenes, biological studies
Polyphosphazenes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(excipients in drug delivery vehicles for depot gels)
IT Drug delivery systems
(gels, sustained-release; excipients in drug delivery vehicles for depot gels)
IT Polyethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho ester group-containing; excipients in drug delivery vehicles for

depot gels)
IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphorus-containing; excipients in drug delivery vehicles for depot gels)
IT Ketals
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; excipients in drug delivery vehicles for depot gels)
IT 50-81-7, Ascorbic acid, biological studies 52-90-4, L-Cysteine, biological studies 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol, biological studies 58-95-7, α-Tocopherol acetate 59-02-9, α-Tocopherol 60-01-5, Tributyrin 62-54-4, Calcium acetate 63-68-3, L-Methionine, biological studies 67-68-5, Dmso, biological studies 68-12-2, Dmf, biological studies 75-21-8, Oxirane, biological studies 75-56-9, Methyloxirane, biological studies 77-89-4, Acetyl triethyl citrate 77-93-0, Triethyl citrate 77-94-1, Tributyl citrate 78-40-0, Triethyl phosphate 78-93-3, Mek, biological studies 79-20-9, Methyl acetate 84-66-2, Diethyl phthalate 87-91-2, Diethyl tartrate 94-13-3, Propylparaben 96-48-0, Butyrolactone 96-49-1, Ethylene carbonate 97-64-3, Ethyl lactate 100-51-6, Benzyl alcohol, biological studies 102-76-1, Triacetin 105-60-2, Caprolactam, biological studies 107-21-1, Ethylene glycol, biological studies 108-32-7, Propylene carbonate 109-99-9, Thf, biological studies 111-87-5, 1-Octanol, biological studies 112-80-1, Oleic acid, biological studies 120-51-4, Benzyl benzoate 121-79-9, Propyl gallate 128-37-0, Bht, biological studies 128-39-2, 2,6-Di-tert-butylphenol 137-66-6, Ascorbyl palmitate 141-43-5, Ethanolamine, biological studies 141-78-6, Ethyl acetate, biological studies 142-17-6, Calcium oleate 142-72-3, Magnesium acetate 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 547-66-0, Magnesium oxalate 557-07-3, Zinc oleate 557-34-6, Zinc acetate 563-72-4 616-45-5, 2-Pyrrolidone 814-80-2, Calcium lactate 831-61-8, Ethyl gallate 872-50-4, N-Methyl-2-pyrrolidone, biological studies 1034-01-1, Octyl gallate 1166-52-5, Lauryl gallate 1300-71-6, Dimethylphenol 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1398-61-4, Chitin 1406-18-4, Vitamin E **1421-63-2**, Trihydroxybutyrophenone 1555-53-9, Magnesium oleate 2474-72-8D, Hydroxyquinone, butylated 3079-28-5, Decyl methyl sulfoxide 3486-35-9, Zinc carbonate 4740-78-7, 1,3-Dioxan-5-ol 5464-28-8, 1,3-Dioxolane-4-methanol 7344-42-5, Zinc maleate 7757-86-0, Magnesium hydrogen phosphate 7757-93-9, Monocalcium phosphate 7758-23-8, Monocalcium phosphate 7779-90-0, Zinc phosphate 9003-29-6, Polybutene 9003-39-8, Pvp **9004-61-9**, **Hyaluronic acid** 9012-76-4, Chitosan 10043-83-1, Magnesium phosphate 10103-46-5, Calcium phosphate 14332-60-6, Zinc hydrogen phosphate 16039-53-5, Zinc lactate 18917-93-6, Magnesium lactate 22329-43-7, Magnesium maleate 23693-48-3, Zinc oxalate 24968-12-5, Polybutylene terephthalate 24980-41-4, Polycaprolactone 25013-16-5, Bha 25248-42-4, Polycaprolactone 25322-68-3, Peg 25395-31-7, Diacetin 25795-42-0, Cepham 26009-03-0, Polyglycolide 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26062-94-2, Polybutylene terephthalate 26161-42-2 26202-08-4, Polyglycolide 26680-10-4, Polylactide 26780-50-7, Lactide-glycolide copolymer 29223-92-5 30846-39-0, Glycolide-L-lactide copolymer 31621-87-1, Polydioxanone 33135-50-1, Poly(L-lactide) 34938-90-4, Calcium maleate 43070-85-5, Hydroxycoumarin 59227-89-3, Azone 70524-20-8, Caprolactone-lactide copolymer 78644-42-5, Poly(malic acid)
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(excipients in drug delivery vehicles for depot gels)
IT 7440-66-6D, Zinc, complexes with somatotropin 9002-72-6D, Somatotropin, zinc complexes 38396-39-3, Bupivacaine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(excipients in drug delivery vehicles for depot gels)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Brodbeck; US 6130200 A 2000 HCAPLUS
(2) Soff; US 5801012 A 1998 HCAPLUS
IT **1421-63-2**, Trihydroxybutyrophenone **9004-61-9**,
Hyaluronic acid
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(excipients in drug delivery vehicles for depot gels)
RN 1421-63-2 HCAPLUS
CN 1-Butanone, 1-(2,4,5-trihydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L30 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:324038 HCAPLUS
DN 142:397825
ED Entered STN: 15 Apr 2005
TI Biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers
IN Horres, Roland; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato
PA Hemoteq G.m.b.H., Germany
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61L027-00
CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 38
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005032611	A2	20050414	WO 2004-DE2184	20040929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004020856	A1	20050414	DE 2004-102004020856	20040428
	US 2005129731	A1	20050616	US 2004-979977	20041103
PRAI	DE 2003-10345132	A	20030929		
	US 2003-516295P	P	20031103		
	DE 2004-102004020856	A	20040428		
	US 2004-571582P	P	20040517		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005032611	ICM	A61L027-00
DE 102004020856	ECLA	A61L031/10+C08L81/06; A61L033/06D+C08L81/06

US 2005129731 NCL 424/423.000

AB The invention relates to medical products comprising at least one biocompatible biostable polysulfone coating. Said polysulfone coating makes it possible, via the admixt. of an adequate quantity of at least one hydrophilic polymer, to control the elution kinetics of the at least one antiproliferative, anti-inflammatory, antiphlogistic, and/or antithrombogenic agent that is introduced and/or applied while allowing different agents or agent concns. to be spatially separated with the aid of the layer system of biostable polymers. Also disclosed are a method for producing said medical products and the use thereof particularly in the form of stents for preventing restenosis. Thus a 2 g base-coat solution for spray coating contained 17.6 mg polyethersulfone(Udel form Solvay) in chloroform. The 3 g chloroformic topcoat solution included 25.2 g polyethersulfone and 1,2 mg PVP.

ST medical implant stent coating polyethersulfone hydrophilicity polymer biocompatibility

IT Ricins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Antisense oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bcl-xL; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Cadherins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E-; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GpIIb/IIIa -Platelet membrane receptor; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Collagens, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-hydroxysuccinimide derivs.; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Transcription factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NF-κB (nuclear factor of κ light chain gene enhancer in B-cells); biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Calcium-binding proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S-100; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Platelet-derived growth factors
Vitronectin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Medical goods
(antithrombogenic; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(b-myc-Antisense; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 5-HT antagonists
Anti-inflammatory agents
Antibiotics
Anticoagulants
Antihistamines
Antipyretics
Antitumor agents

Antiviral agents
Biocompatibility
Coating materials
Fungicides
Human
Hydrophilicity
Porosity
Porous materials
Vasodilators
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Albumins, biological studies
Caseins, biological studies
Collagens, biological studies
Fibrinogens
Fibrins
Gelatins, biological studies
Lipids, biological studies
Polyanhydrides
Polyanhydrides
Polycarbonates, biological studies
Polyesters, biological studies
Polyoxyalkylenes, biological studies
Polyphosphazenes
Polysulfones, biological studies
Polyurethanes, biological studies
Rubber, biological studies
Zeins
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Antisense oligonucleotides
Prostaglandins
Protamines
Selectins
Steroids, biological studies
Sulfonamides
Terpenes, biological studies
Tocopherols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polysulfones, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(block copolymers; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(block; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(c-myc- Antisense; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Triterpenes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carboxy, boswellic acids; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polysulfones, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chlorosulfonated/S-alkoxy dechlorinated; biocompatible, biostable

coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, inhibitors of; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Macrolides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilones, A and B; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycolide-based; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polycarbonates, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imino-; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Drug delivery systems
Prosthetic materials and Prosthetics
(implants; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Apoptosis
(inhibitors; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Anti-inflammatory agents
(nonsteroidal; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyethers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho ester group-containing; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyolefins
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p65; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polysulfones, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perfluorinated; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphoesters; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyamides, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly(amino acids); biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyamide-; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Polyamides, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyester-; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Phenols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyphenols, nonpolymeric, from tea; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Artery, disease
(restenosis; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Muscle
(smooth, cell, inhibitors of; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Coating process
(spray; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Medical goods
(stents; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triterpene, boswellic acids; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 71695-69-7, Baccharinoid B 1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Baccharinoid B 1; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 71748-64-6, Baccharinoid B 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Baccharinoid B 2; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 72074-16-9, Baccharinoid B 3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Baccharinoid B 3; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 71718-23-5, Baccharinoid B 7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Baccharinoid B 7; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT 155486-20-7, Cryptophycin E
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cryptophycin E; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT 106096-93-9, BFGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT 141-43-5, Seramine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT 99331-25-6, Triazolopyrimidine
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT 56-81-5, Glycerin, biological studies 80-05-7D, iminocarbonate polymers 3233-46-3 6066-82-6D, derivs. of collagen 7585-39-9, β-Cyclodextrin 9000-01-5, Gum arabic 9000-07-1, Carrageenan 9000-69-5, Pectinic acid 9002-89-5, Polyvinylalcohol 9003-05-8, Polyacrylamide 9003-11-6 9003-39-8, Polyvinylpyrrolidone 9004-54-0, Dextran, biological studies **9004-61-9, Hyaluronic acid** 9005-25-8, Starch, biological studies 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9012-76-4, Chitosan 9012-76-4D, Chitosan, N-carboxymethylated/acetylated 24937-72-2, Polymaleic acid anhydride 24980-41-4, Poly-ε-caprolactone 25135-51-7 25248-42-4, Poly[oxy(1-oxo-1,6-hexanediyl)] 25249-16-5 25322-68-3, Polyethyleneglycol 25322-69-4, Polypropyleneglycol 25667-42-9, Polyethersulfone 25667-42-9D, Polyethersulfone, substituted derivative 26009-03-0, Polyglycolic acid 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26099-09-2 26100-51-6, Polylactic acid 26124-68-5, Polyglycolic acid 26354-94-9, Polyvalerolactone 27030-79-1 27613-96-3 29223-92-5 31852-84-3 37353-50-7 50862-75-4, Poly(oxycarbonyloxy-1,3-propanediyl) 51309-43-4 52224-87-0 52352-27-9, Polyhydroxybutyric acid 53260-52-9, N-Desulfo heparin 53260-52-9D, N-Desulfo heparin, reacetylated 61128-18-5 67183-98-6, Polyphenylsulfone 67183-98-6D, Polyphenylsulfone, substituted derivative 90409-77-1 102190-94-3, Polyhydroxyvaleric acid 113883-69-5 128171-16-4 143715-04-2 159350-71-7, Poly-ε-Decalactone 214259-59-3
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT 50-02-2, Dexamethasone 50-07-7, Mutamycin 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-27-1, Estriol 50-28-2, β-Estradiol, biological studies 50-33-9, Phenylbutazon, biological studies 50-50-0, Estradiolbenzoate 50-63-5, Chloroquine phosphate 50-76-0, Dactinomycin 50-78-2, Aspirin 51-06-9, Procainamide 51-21-8, Fluorouracil 52-24-4, Thiotepa 52-53-9, Verapamil 52-67-5, Penicillamine 53-16-7, Estron, biological studies 53-86-1, Indomethacin 54-05-7, Chloroquine 55-98-1, Busulfan 56-54-2, Quinidine 57-22-7, Vincristin 57-63-6, Ethinylestradiol 57-91-0, α-Estradiol 58-32-2, Dipyridamole 59-05-2, Methotrexate 60-54-8, Tetracycline 61-33-6, biological studies 61-68-7, Mefenamic acid 64-86-8, Colchicine 66-79-5, Oxacillin 77-52-1, Ursolic acid 78-11-5, Pentaerythrityltetranitrate 80-08-0, Dapson 81-81-2, Warfarin 83-46-5, β-Sitosterin 84-79-7, Lapachol 92-61-5, Scopoletin 93-35-6, Umbelliferon 94-09-7, Benzocaine 108-28-1, Protoanemonin 118-42-3, Hydroxychloroquine 124-94-7, Triamcinolone 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-07-1, Hydroxycarbamide 129-06-6, Coumadin 130-95-0,

Quinine 137-58-6, Lidocaine 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 299-75-2, Treosulfan 302-79-4, Tretinoin 303-34-4, Lasiocarpine 305-03-3, Chlorambucil 313-06-4, Estradiolcypionate 378-44-9, Betamethasone 443-48-1, Metronidazol 446-86-6, Azathioprin 458-37-7, Curcumin 472-15-1, Betulinic acid 473-98-3, Betulin 475-75-2, Liriodenine 477-30-5 480-82-0, Indicine 481-49-2, Cepharantin 500-68-5, Bilobol 501-26-8, Ginkgol 504-64-3D, Carbon suboxide, macrocyclic oligomers 508-44-1, Anemonine 518-28-5, Podophyllotoxin 519-23-3, Ellipticine 520-85-4, Medroxyprogesteron 522-40-7, Fosfestrol 550-79-8, Afromosin 566-48-3, Formestane 599-79-1, Sulfasalazine 671-16-9, Procarbazine 863-03-6, Epicatechingallate 865-21-4, Vinblastin 989-51-5, Epigallocatechingallate 1177-14-6 1400-61-9, Nystatin 1403-66-3, Gentamycin 1404-00-8, Mitomycin 1405-87-4, Bacitracin 1508-45-8, Podophyllic acid-2-ethylhydrazide 1951-25-3, Amiodarone 2022-85-7, Flucytosine 2034-69-7, Daphnoretin 2086-83-1, Berberin 2210-63-1, Mofebutazone 2216-51-5, Levomenthol 2444-46-4, Nonivamide 2447-54-3, Sanguinarine 2751-09-9, Troleandomycin 2998-57-4, Estramustine 3116-76-5, Dicloxacillin 3484-37-5, Ovatodiolide 3737-09-5, Disopyramide 3778-73-2, Ifosfamide 3930-20-9, Sotalol 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4707-32-8, β-Lapachone 6754-13-8, Helenalin 6805-41-0, Aescine 7689-03-4, Camptothecin 7712-50-7, Myrtecaine 8001-27-2, Hirudin 8025-81-8, Spiramycin 9001-12-1, Metalloproteinase-1 9002-01-1, Streptokinase 9002-92-0, Polidocanol 9015-68-3, Asparaginase 9039-53-6, Urokinase 9088-07-7, Natriuretic peptide 10540-29-1, Tamoxifen 11037-26-6, Mansonin 11056-06-7, Bleomycin 12244-57-4, Sodium aurothiomalate 13010-47-4, Lomustine 13063-04-2, Nitidine chloride 13063-06-4, Dihydronitidine 14110-64-6, Cytochalasin A 14930-96-2, Cytochalasin B 15078-28-1, Nitroprusside 15307-86-5, Diclofenac 15421-84-8, Trapidil 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 16506-27-7, Bendamustine 16846-24-5, Josamycin 17951-19-8, Justicidin B 19622-83-4, Margetine 20089-98-9 20830-81-3, Daunomycin 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22089-22-1, Trofosfamide 22144-76-9, Cytochalasin C 22144-77-0, Cytochalasin D 22204-53-1, Naproxen 22570-53-2, Zeorin 22910-60-7, Ginkgolic acid 22916-47-8, Miconazole 23214-92-8, Doxorubicin 23288-49-5, Probucol 23593-75-1, Clotrimazole 25001-57-4, Justicidin A 25316-40-9, Adriamycin 25395-22-6, o-Carbamoylphenoxyacetic acid 25717-80-0, Molsidomine 25953-19-9, Cefazolin 27003-73-2, Lariciresinol 29679-58-1, Fenoprofen 29767-20-2, Teniposide 29908-03-0, Ademetionine 30220-43-0, Effusanin A 30508-27-1, Licoricidin 30516-87-1, Zidovudine 31430-18-9, Nocodazole 31441-78-8, Mercaptopurine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 33876-97-0, Sydnonimine-1 33996-33-7, Oxaceprol 34031-32-8, Auranofin 35121-78-9, Prostacyclin 35226-29-0, Usambarine 35457-80-8, Midecamycin 35607-66-0, Cefoxitin 35846-53-8, Maytansine 35963-37-2, Inotodiol 36011-19-5, Cytochalasin E 36150-14-8, Usambarensine 36150-15-9, Dihydrousambarensine 36322-90-4, Piroxicam 38748-32-2, Triptolide 38927-54-7, Isodeoxyelephantopin 40277-05-2, 4-Hydroxycyclophosphamide 41451-91-6, Erythromycine 41575-94-4, Carboplatin 41708-76-3, Indicine-N-oxide 42471-28-3, Nimustine 42617-41-4, Activated Protein C 50370-12-2, Cefadroxil 51110-01-1, Somatostatin 51264-14-3, Amsacrine 53123-88-9, Rapamycin 53164-05-9, Acemetacin 53230-10-7, Mefloquine 53643-48-4, Vindesine 53808-88-1, Lonazolac 53902-12-8, Tranilast 53910-25-1, Pentostatin 53948-07-5, Aristolactam-AII 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide 55837-20-2, Halofuginone 56420-45-2, Epirubicin 56519-07-4, Akagerine 57576-44-0, Aclarubicin 58066-85-6, Miltefosine 58581-89-8, Azelastine 58957-92-9, Idarubicin 59015-79-1, Strebloside 59277-89-3, Acyclovir 59865-13-3, Cyclosporin A 60706-78-7, Hydroxyanopterine 61825-94-3, Oxaliplatin 62571-86-2, Captopril 62993-59-3, 5-O-Methylsorbifolin 62996-74-1, Staurosporin 63209-34-7, Strychnopentamine 65277-42-1, Ketoconazole 66107-60-6, Baccatin 67763-96-6, IGF-1 69306-88-3, Strychnophylline 70322-87-1, Vismione B 70322-88-2, Vismione A 71125-38-7, Meloxicam 71142-71-7, PPACK 71486-22-1, Vinorelbine

Search done by Noble Jarrell

73211-35-5 73981-34-7, Kamebakaurin 74863-84-6, Argatroban
75207-66-8, Longikaurin B 75330-75-5, Lovastatin 75607-67-9
75706-12-6, Leflunomide 75847-73-3, Enalapril
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 76547-98-3, Lisinopril 78536-36-4, Excisanin B 78536-37-5, Excisanin A
79439-84-2, Yadanzioside P 79498-26-3, Leukamenin A 79498-27-4,
Leukamenin B 79902-63-9, Simvastatin 80214-83-1, Roxithromycin
80890-47-7, Concanamycin 81093-37-0, Pravastatin 81103-11-9,
Clarithromycin 82151-95-9D, derivs. 82410-32-0, Ganciclovir
82657-92-9, Prourokinase 83905-01-5, Azithromycin 84316-84-7,
Maytenfoliol 85287-59-8, Sculponeatin C 85505-64-2, Vapiprost
85622-93-1, Temozolomide 85721-33-1, Ciprofloxacin 86293-25-6,
Iso-Iridogermanal 88418-46-6, Marchantin A 88768-40-5, Cilazapril
91161-71-6, Terbinafine 93957-54-1, Fluvastatin 94450-14-3,
Acetylvismione B 95058-81-4, Gemcitabine 96203-70-2, Pancratistatin
97682-44-5, Irinotecan 97915-43-0, 1-Hydroxy-11-Methoxycanthin-6-one
98932-70-8, Folimycin 99283-10-0, Molgramostim 101391-05-3, Bruceanol
B 101391-06-4, Bruceanol A 101560-00-3, Yadanzioside N 101809-47-6,
Mansonin E 102040-03-9D, derivs. 102567-16-8 102904-16-5,
Mallotochromanol **102904-17-6**, Mallotolerin 103839-24-3,
1,11-Dimethoxycanthin-6-one 104987-11-3, Tacrolimus 104987-12-4,
Ascomycin 105608-32-0, Bryophyllin A 105661-18-5, Hippocaesculin
107868-30-4, Exemestane 108736-35-2, Angiopeptin 108864-22-8,
Tomenphantopin A 108864-23-9, Tomenphantopin B 109237-00-5,
Stizophyllin 109351-36-2, Sinococuline 110024-07-2, Agrostistachin
110187-24-1, Maquiroside A 110300-76-0, Taxamairin A 110300-77-1,
Taxamairin B 110942-02-4, Aldesleukin 112078-76-9, Bisparthenolidine
112809-51-5, Letrozole 112899-35-1, Bruceantinoside C 114076-69-6,
Agroskerin 114076-70-9 114076-71-0 114586-21-9, Bruceanol C
114727-97-8, Cudraisoflavone A 114798-26-4, Losartan 114828-46-5,
Periplocoside A 114977-28-5, Docetaxel 116963-87-2, Manwuweizic acid
118711-55-0, Hyptatic acid A 119188-33-9, Coronarin A 119188-35-1,
Coronarin C 119188-37-3, Coronarin D 119188-38-4, Coronarin B
119459-76-6, Ghalakinoside 120511-73-1, Anastrozole 121181-53-1,
Filgrastim 123948-87-8, Topotecan 127830-04-0, C-type natriuretic
peptide 128270-60-0, Bivalirudin 128794-94-5, Mycophenolate mofetil
129399-53-7, Isobutyrylmallotochromanol 130062-03-2,
Larreatricin 130167-69-0, Pegaspargase 134523-00-5, Atorvastatin
135968-09-1, Lenograstim 139639-23-9, Tissue plasminogen activator
143090-92-0, Anakinra 143653-53-6, Abciximab 145599-86-6, Cerivastatin
146480-35-5, Gelatinase A 147511-69-1, Pitavastatin 151499-39-7,
Bafilomycin 152923-56-3, Daclizumab 153212-75-0, 6-α-Hydroxy-
Paclitaxel 154361-50-9, Capecitabine 159351-69-6, Everolimus
169590-42-5, Celecoxib 178603-78-6 179045-86-4, Basiliximab
185077-23-0, PI 88 185243-69-0, Etanercept 186256-67-7, Cryptophycin
52 204205-90-3, D-24851 215647-85-1 265646-19-3, Indanocine
287714-41-4, Rosuvastatin 305838-77-1, Neovastat 528900-03-0, Anginex
643017-29-2 679809-58-6, Enoxaparin sodium 849777-84-0 849777-86-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 9002-05-5, Blood-coagulation factor Xa
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor antibody; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 80449-02-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 9015-82-1 37353-41-6, Thioprotease 127464-60-2, Vascular endothelial growth factor 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)

IT 9054-75-5, Guanylyl cyclase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stimulator, tissue inhibitor; biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
IT **9004-61-9, Hyaluronic acid**
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **102904-17-6**, Mallotolerin **129399-53-7**, Isobutyrylmallotochromanol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible, biostable coating of medical surfaces composed of polysulfone and hydrophilic polymers)
RN 102904-17-6 HCAPLUS
CN 1-Butanone, 1-[3-[(3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-2,4,6-trihydroxy-5-(2-hydroxy-3-methyl-3-butenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 129399-53-7 HCAPLUS
CN 1-Propanone, 1-[6-[(3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-3,4-dihydro-3,5,7-trihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-2-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:531324 HCAPLUS
DN 141:94004
ED Entered STN: 02 Jul 2004
TI Use of an alkyl ether of hydroxystilbene for the treatment of dry skin
IN Dalko, Maria; Rubinstenn, Gilles
PA L'oreal, Fr.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent

LA English
IC ICM A61K007-48
ICS A61P017-00; A61K031-085; A61K031-09
CC 62-4 (Essential Oils and Cosmetics)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054533	A1	20040701	WO 2003-EP12507	20031110
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2848844	A1	20040625	FR 2002-16113	20021218
	FR 2848844	B1	20050506		
PRAI	FR 2002-16113	A	20021218		
	US 2003-438775P	P	20030109		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004054533	ICM	A61K007-48
	ICS	A61P017-00; A61K031-085; A61K031-09
WO 2004054533	ECLA	A61K008/33; A61Q019/00; A61Q019/08
FR 2848844	ECLA	A61K008/33; A61Q019/00; A61Q019/08

OS MARPAT 141:94004
AB The present invention relates to a method for the cosmetic treatment of dry skin or of a dry scalp, comprising the topical application to the skin or the scalp of a composition containing, in a physiol. acceptable medium, at least one alkyl ether of hydroxystilbene with a saturated or unsatd., linear or branched C1-C6 alc. The composition may be used for cosmetic purposes, for treating drying out of the skin, in particular after the menopause, or for dermatol. purposes, for treating disorders associated with oligoseborrheic dry skin, in particular forms of dermatitis. Resveratrol tri-Me ether (I) induced an increase in sebocytic lipogenesis. A cosmetic composition was prepared containing I.
ST hydroxy stilbene alkyl ether dry skin; cosmetic dry skin resveratrol trimethyl ether
IT Antibacterial agents
Cosmetics
Sophora japonica
(an alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Carboxylic acids, biological studies
Fatty acids, biological studies
Glycosphingolipids
Lecithins
Phospholipids, biological studies
Polysaccharides, biological studies
Steroids, biological studies
Terpenes, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(an alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Skin, disease
(dry; an alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Cosmetics
(moisturizers; an alkyl ether of hydroxystilbene for the treatment of dry skin)
IT 22255-22-7, Resveratrol trimethyl ether
RL: BSU (Biological study, unclassified); COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(an alkyl ether of hydroxystilbene for the treatment of dry skin)

IT 50-21-5, Lactic acid, biological studies 53-43-0, Dhea 56-45-1, L-Serine, biological studies 56-81-5, Glycerol, biological studies 57-13-6, Urea, biological studies 57-88-5, Cholesterol, biological studies 60-00-4, Edta, biological studies 69-72-7, Salicylic acid, biological studies 72-17-3, Sodium lactate 77-52-1, Ursolic acid 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 83-46-5, β-Sitosterol 83-48-7, Stigmasterol 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 90-64-2, Mandelic acid 122-99-6, Phenoxyethanol 123-99-9, Azelaic acid, biological studies 154-92-7, N-α-Benzoyl-L-arginine 472-15-1, Betulinic acid 474-62-4, Campesterol 490-79-9, Gentisic acid 491-37-2, 4-Chromanone 501-36-0, Resveratrol 508-02-1, Oleanolic acid 621-82-9, Cinnamic acid, biological studies 1117-86-8, Caprylyl glycol 1406-16-2, Vitamin d 1449-05-4, β-Glycyrrhetinic acid 3380-34-5, Triclosan 4602-84-0, Farnesol 6915-15-7, Malic acid 7365-45-9, Hepes 7512-17-6, N-Acetylglucosamine **9004-61-9**, **Hyaluronic acid** 9012-76-4, Chitosan 10438-94-5, Octoxy glycerin 14246-53-8 19771-63-2, Procysteine 28874-51-3, Sodium pidolate 29348-79-6, Pentanediol 52357-35-4 77554-84-8, Sodium methylglycine diacetate **78418-01-6**, 5-Octanoylsalicylic acid 96702-03-3, Ectoin 131334-66-2 153490-07-4 607717-56-6
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(an alkyl ether of hydroxystilbene for the treatment of dry skin)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Inaoka, Y; JP 01038009 A 1989 HCAPLUS
(2) Johnson & Johnson Consumer; WO 0143705 A 2001 HCAPLUS
(3) Oreal; EP 0953344 A 1999 HCAPLUS
(4) Oreal; EP 1029530 A 2000 HCAPLUS
(5) Ptchelintsev, D; WO 03055444 A 2003
(6) Rossi, F; WO 0191695 A 2001 HCAPLUS
(7) Rossi, F; WO 0191714 A 2001 HCAPLUS

IT **9004-61-9**, **Hyaluronic acid** **78418-01-6**, 5-Octanoylsalicylic acid
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(an alkyl ether of hydroxystilbene for the treatment of dry skin)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 78418-01-6 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxooctyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:512212 HCAPLUS
DN 141:76375
ED Entered STN: 25 Jun 2004
TI Use of an alkyl ether of hydroxystilbene for the treatment of dry skin
IN Dalko, Maria; Rubinstenn, Gilles
PA L'oreal, Fr.
SO Fr. Demande, 21 pp.
CODEN: FRXXBL

DT Patent
LA French
IC ICM A61K007-40
ICS A61K007-06
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2848844	A1	20040625	FR 2002-16113	20021218
	FR 2848844	B1	20050506		
	WO 2004054533	A1	20040701	WO 2003-EP12507	20031110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI FR 2002-16113 A 20021218
US 2003-438775P P 20030109

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2848844	ICM	A61K007-40
	ICS	A61K007-06
FR 2848844	ECLA	A61K008/33; A61Q019/00; A61Q019/08
WO 2004054533	ECLA	A61K008/33; A61Q019/00; A61Q019/08

OS MARPAT 141:76375
AB The present invention relates to a cosmetic process of treatment of dry skin or dry scalp, including the topical application on the skin or the scalp, of a composition containing at least one alkyl ether of hydroxystilbene with a C1-6 alc., linear or branched, saturated or unsatd. The composition can be used with fine cosmetics, to treat the drying of the skin, in particular after menopause, or for dermatol. purposes, for the treatment of disorders related to oligoseborrheic dry skin, in particular dermatitis.
ST dermatitis dry skin cosmetic hydroxystilbene alkyl ether
IT Antibacterial agents
Cosmetics
Honey
Seborrhea
(alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Ceramides
Diglycerides
Glycosphingolipids
Lanolin
Lecithins
Petrolatum
Phospholipids, biological studies
Sphingolipids
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Natural products, pharmaceutical
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Scalp
Skin, disease
(dry; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Cosmetics
(emulsions; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Fatty acids, biological studies

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(essential; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Paeonia lactiflora
Paeonia suffruticosa
Sophora japonica
(exts.; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Embryophyta
(medicinal plant; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Cosmetics
(moisturizers; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Triterpenes
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(pentacyclic; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT Sterols
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(phyto-; alkyl ether of hydroxystilbene for the treatment of dry skin)
IT 50-21-5, Lactic acid, biological studies 53-43-0, Dhea 56-40-6D, Glycine, derivs. 56-45-1, Serine, biological studies 57-13-6, Urea, biological studies 57-88-5D, Cholesterol, derivs. 60-00-4, Edta, biological studies 72-17-3, Sodium lactate 77-52-1, Ursolic acid 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 83-46-5, β-Sitosterol 83-48-7, Stigmasterol 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 90-64-2, Mandelic acid 99-20-7, Trehalose 474-62-4, Campesterol 490-79-9, Gentisic acid 491-37-2, 4-Chromanone 501-36-0, Resveratrol 621-82-9, Cinnamic acid, biological studies 2438-80-4D, Fucose, oligomers 6915-15-7, Malic acid 7365-45-9, Hepes 7512-17-6, N-Acetylglucosamine **9004-61-9, Hyaluronic acid** 9012-76-4, Chitosan 19750-45-9, 2-Oxothiazolidine-4-carboxylic acid 28874-51-3, Sodium pidolate 29348-79-6, Pentanediol **78418-01-6**, n-Octanoyl 5-salicylic acid 96702-03-3, Ectoin 153490-07-4
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(alkyl ether of hydroxystilbene for the treatment of dry skin)
IT 30498-85-2D, Hydroxystilbene, alkyl ethers
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl ether of hydroxystilbene for the treatment of dry skin)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Inaoka, Y; JP 01-038009 A 1989 HCAPLUS
(2) Johnson and Johnson Consumer; WO 0143705 A HCAPLUS
(3) Oreal; EP 0953344 A 1999 HCAPLUS
(4) Oreal; EP 1029530 A 2000 HCAPLUS
(5) Ptchelintsev, D; WO 03055444 A 2003
(6) Rossi, F; WO 0191695 A 2001 HCAPLUS
(7) Rossi, F; WO 0191714 A 2001 HCAPLUS
IT **9004-61-9, Hyaluronic acid 78418-01-6**
, n-Octanoyl 5-salicylic acid
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(alkyl ether of hydroxystilbene for the treatment of dry skin)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 78418-01-6 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxooctyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:498643 HCAPLUS
DN 142:43627
ED Entered STN: 21 Jun 2004
TI Characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds
AU Leach, Jennie B.; Schmidt, Christine E.
CS Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, 78712, USA
SO Biomaterials (2004), Volume Date 2005, 26(2), 125-135
CODEN: BIMADU; ISSN: 0142-9612
PB Elsevier Science Ltd.
DT Journal
LA English
CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 35
AB The goal of this work was to utilize the naturally derived bioactive polymer **hyaluronic acid** (HA) to create a combination tissue engineering scaffold and protein delivery device. HA is a non-immunogenic, non-adhesive glycosaminoglycan that plays significant roles in several cellular processes, including angiogenesis and the regulation of inflammation. In previous work, we created photopolymerizable glycidyl methacrylate-**hyaluronic acid** (GMHA) hydrogels that had controlled degradation rates, were cytocompatible, and were able to be modified with peptide moieties. In the present studies, we characterized the release of a model protein, bovine serum albumin (BSA), from GMHA and GMHA-polyethylene glycol (PEG) hydrogels. Although BSA could be released rapidly (>60% within 6 h) from 1% GMHA hydrogels, we found that increasing either the GMHA or the PEG concns. could lengthen the duration of protein delivery. Preliminary size exclusion chromatog. studies indicated that the released BSA was almost entirely in its native monomeric form. Lastly, protein release was extended to several weeks by suspending BSA-poly(lactic-co-glycolic acid) microspheres within the hydrogel bulk. These initial studies indicate that the naturally derived biopolymer HA can be employed to design novel photopolymerizable composites that are suitable for delivering stable proteins from scaffolding in tissue engineering applications.
ST serum albumin crosslinked **hyaluronic acid** PEG hydrogel tissue engineering
IT Composites
Diffusion
Dissolution
Hydrogels
Microspheres
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)
IT Animal tissue
(engineering; characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)
IT Polyesters, biological studies
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(hydroxycarboxylic acid-based; characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

IT Prosthetic materials and Prosthetics
(implants, scaffolds for tissue engineering; characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

IT Albumins, biological studies
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serum, bovine; characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

IT **106797-53-9**, **Irgacure** 2959
RL: CAT (Catalyst use); USES (Uses)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

IT 51728-26-8P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

IT 34346-01-5, Glycolic acid-lactic acid copolymer **478369-82-3**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

IT 106-91-2, Glycidyl methacrylate **9004-61-9**, **Hyaluronic acid**
RL: RCT (Reactant); RACT (Reactant or reagent)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Amsden, B; Macromolecules 1998, V31, P8382 HCAPLUS
(2) Andreopoulos, F; Biotechnol Bioeng 1999, V65, P579 HCAPLUS
(3) Andrianov, A; Biomaterials 1998, V19, P109 HCAPLUS
(4) Azegami, S; Langmuir 1999, V15, P940 HCAPLUS
(5) Baier Leach, J; Biotechnol Bioeng 2003, V82, P578
(6) Bos, G; Pharmaceutical Technol North Am 2001, V25, P110 HCAPLUS
(7) Castellanos, I; J Pharm Pharmacol 2001, V53, P1099 HCAPLUS
(8) Chorny, R; Ind Eng Chem Process Des Dev 1966, V5, P206 HCAPLUS
(9) Cleland, J; Curr Opin Biotechnol 2001, V12, P212 HCAPLUS
(10) Costantino, H; Pharm Res 2000, V17, P1374 HCAPLUS
(11) Crank, J; The mathematics of diffusion 1975
(12) Cruise, G; Biomaterials 1998, V19, P1287 HCAPLUS
(13) Davis, B; Proc Natl Acad Sci USA 1974, V71, P3120 HCAPLUS
(14) Ghezzo, E; Int J Pharm 1992, V87, P21 HCAPLUS
(15) Gombotz, W; Bioconj Chem 1995, V6, P332 HCAPLUS
(16) Griffith, L; Science 2002, V295, P1009 HCAPLUS
(17) Han, J; J Agric Food Chem 2000, V48, P5658 HCAPLUS
(18) Hatefi, A; J Control Release 2002, V80, P9 HCAPLUS
(19) Hern, D; J Biomed Mater Res 1998, V39, P266 HCAPLUS
(20) Hubbell, J; Biotechnology (NY) 1995, V13, P565 HCAPLUS
(21) Hubbell, J; J Control Release 1996, V39, P305 HCAPLUS
(22) Inukai, M; Chem Pharm Bull (Tokyo) 2000, V48, P850 HCAPLUS
(23) Jacobsen, S; Exp Neurol 1965, V11, P48
(24) Jain, R; Biomaterials 2000, V21, P2475 HCAPLUS
(25) Jin, Y; J Control Release 2001, V73, P173 HCAPLUS
(26) Johnson, O; Encyclopedia of controlled drug delivery 1999, P816
(27) Kim, B; Trends Biotechnol 1998, V16, P224 HCAPLUS

(28) Kim, H; J Biomed Mater Res 2002, V59, P573 HCAPLUS
(29) Kim, M; J Control Release 2002, V80, P69 HCAPLUS
(30) Kwon, Y; Pharm Res 2001, V18, P1754 HCAPLUS
(31) Larsen, N; Adv Drug Deliv Rev 1991, V7, P279 HCAPLUS
(32) Leach, J; Encyclopedia of biomaterials and biomedical engineering, in press
(33) Leach, J; J Biomed Mater Res, in press
(34) Leach, W; Uniform encapsulation of protein nanoparticles produced by spray freezing for the reduction of burst, submitted for publication
(35) Lee, K; Chem Rev 2001, V101, P1869 HCAPLUS
(36) Lowman, A; J Biomater Sci Polym Ed 1999, V10, P999 HCAPLUS
(37) Mann, B; J Biomed Mater Res 2002, V60, P86 HCAPLUS
(38) Mellott, M; Biomaterials 2001, V22, P929 HCAPLUS
(39) Narasimhan, B; Encyclopedia of controlled drug delivery 1999, P921
(40) Perez, C; J Pharm Pharmacol 2002, V54, P301 HCAPLUS
(41) Perez-Rodriguez, C; J Control Release 2003, V89, P71 HCAPLUS
(42) Peters, T; All about albumin 1996
(43) Politis, M; Brain Res 1982, V253, P1 MEDLINE
(44) Ratner, B; J Control Release 2002, V78, P211 HCAPLUS
(45) Reinhart, C; J Memb Sci 1984, V18, P227 HCAPLUS
(46) Rowley, J; J Biomed Mater Res 2002, V60, P217 HCAPLUS
(47) Saffran, M; Science 1986, V233, P1081 HCAPLUS
(48) Simon, L; J Control Release 1999, V61, P267 HCAPLUS
(49) Vercruysse, K; Crit Rev Ther Drug Carrier Syst 1998, V15, P513 HCAPLUS
(50) Xu, S; Chem Pharm Bull (Tokyo) 2000, V48, P779 HCAPLUS
(51) Yu, Z; Eur J Pharm Biopharm 2002, V54, P221 HCAPLUS
(52) Yu, Z; Spray freezing into liquid for highly stable protein nanostuctured microparticles, submitted for publication
(53) Zhu, G; Pharm Res 2000, V17, P351 HCAPLUS

IT **106797-53-9, Irgacure 2959**
RL: CAT (Catalyst use); USES (Uses)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

RN 106797-53-9 HCAPLUS

CN 1-Propanone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



IT **478369-82-3**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)

RN 478369-82-3 HCAPLUS

CN Hyaluronic acid, 2-hydroxy-3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-61-9
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 5919-74-4
CMF C7 H12 O4



IT **9004-61-9, Hyaluronic acid**
RL: RCT (Reactant); RACT (Reactant or reagent)
(characterization of protein release from photocrosslinkable **hyaluronic acid**-polyethylene glycol hydrogel tissue engineering scaffolds)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L30 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:779072 HCAPLUS
DN 139:296978
ED Entered STN: 05 Oct 2003
TI A sapogenin or a natural extract containing it for the treatment of oligoseborrheic dry skin
IN Rubinstenn, Gilles; Buan, Bruno
PA L'Oreal, Fr.
SO Fr. Demande, 23 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM A61K007-48
ICS A61K007-06
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 62
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2837704	A1	20031003	FR 2002-4072	20020402
	FR 2837704	B1	20050114		
	EP 1375509	A1	20040102	EP 2003-290709	20030320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2003216327	A1	20031120	US 2003-393989	20030324
	JP 2003300862	A2	20031021	JP 2003-98389	20030401
PRAI	FR 2002-4072	A	20020402		
	US 2002-374159P	P	20020422		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2837704	ICM	A61K007-48
	ICS	A61K007-06
FR 2837704	ECLA	A61K008/63; A61K008/97; A61Q019/00; A61Q019/08; C07J071/00; C07J075/00
EP 1375509	ECLA	A61K008/63; A61K008/97; A61Q019/00; A61Q019/08; C07J071/00; C07J075/00
US 2003216327	NCL	514/026.000
	ECLA	A61K008/63; A61K008/97; A61Q019/00; A61Q019/08; C07J071/00; C07J075/00

AB The present invention relates to the use of a composition containing at least a sapogenin, or a natural extract containing the sapogenin for the treatment of the oligoseborrheic dry skin or dry scalp. Cosmetic compns. can be used to treat the dry skin, in particular after menopause, or for the treatment of the disorders related to the oligoseborrheic dry skins, in particular of

the dermatitis. Preferred sapogenins are the hecogenin and the diosgenin. Thus, an ointment contained diosgenin 1, salicylic acid 1, glycerol monostearate 3, propylene glycol 12, petrolatum 82.9, and water qs to 100%.

ST sapogenin natural ext oligoseborrheic dry skin

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Calophyllum; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Echium; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(black currant; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Cosmetics
(creams; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Carbonates, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclo-; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Scalp
Skin, disease
(dry; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Cosmetics
Drug delivery systems
(emulsions; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Fatty acids, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(essential; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Algae
Chamomile
Sophora japonica
(exts.; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Drug delivery systems
(gels, topical; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Cosmetics
Drug delivery systems
(gels; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Carboxylic acids, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Skin
(keratinocyte; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Cosmetics
Drug delivery systems
(lotions; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Cosmetics
(moisturizers; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(musk rose; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Drug delivery systems
(ointments, creams; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Drug delivery systems
(ointments; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Triterpenes
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pentacyclic; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Aloe barbadensis
Anti-inflammatory agents
Antibacterial agents
Bacopa monnieri
Boswellia serrata
Centipeda cunninghamii
Cola nitida
Cosmetics
Dermatitis
Epilobium angustifolium
Helianthus annuus
Iris pallida
Laminaria saccharina
Paeonia lactiflora
Paeonia suffruticosa
Pygeum
Rosa gallica
Rosmarinus officinalis
Seborrhea
Vitreoscilla filiformis
(sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Canola oil
Ceramides
Diglycerides
Glycosphingolipids
Lanolin
Lecithins
Oligosaccharides, biological studies
Petrolatum
Phospholipids, biological studies
Polysaccharides, biological studies
Retinoids
Sterols
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sesame; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)

IT Drug delivery systems
(topical; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unsatd., ω-3; sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT 467-55-0, Hecogenin 512-04-9, Diosgenin 31566-31-1, Glyceryl monostearate
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
IT 50-21-5, Lactic acid, biological studies 50-23-7, HydroCortisone 53-06-5, Cortisone 53-43-0, DHEA 53-43-0D, DHEA, derivs. 53-86-1, Indomethacin 56-45-1, Serine, biological studies 56-81-5, Glycerol, biological studies 57-13-6, Urea, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, derivs. 60-00-4, EDTA, biological studies 60-00-4D, EDTA, acyl derivs. 68-26-8, Retinol 68-26-8D, Retinol, esters 69-72-7, Salicylic acid, biological studies 72-17-3, Sodium lactate 77-52-1, Ursolic acid 77-60-1, Tigogenin 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 83-46-5, β-Sitosterol 83-48-7, Stigmasterol 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 90-64-2, Mandelic acid 97-59-6, Allantoin 99-20-7, Trehalose 99-20-7D, Trehalose, derivs. 122-99-6, Phenoxyethanol 123-99-9, Azelaic acid, biological studies 126-18-1, Smilagenin 126-19-2 154-92-7, N-α-Benzoyl-L-arginine 378-44-9, Betamethasone 472-15-1, Betulinic acid 474-62-4, Campesterol 490-79-9, Gentisic acid 491-37-2, 4-Chromanone 501-36-0, Resveratrol 508-02-1, Oleanolic acid 511-97-7, Yuccagenin 512-06-1, Yamogenin 515-69-5, α-Bisabolol 621-82-9, Cinnamic acid, biological studies 1117-86-8, Caprylyl glycol 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, derivs. 1449-05-4, β-Glycyrrhetinic acid 1449-05-4D, β-Glycyrrhetinic acid, derivs. 4602-84-0, Farnesol 6829-55-6D, Tocotrienol, derivs. 7365-45-9, HEPES 7512-17-6, N-Acetylglucosamine **9004-61-9**, **Hyaluronic acid 9004-61-9D**, **Hyaluronic acid**, derivs. 9012-76-4, Chitosan 10438-94-5, Octoxy glycerin 14246-53-8, Capryloyl glycine 16283-36-6, Zinc Salicylate 19771-63-2, Procysteine 28874-51-3, Sodium pidolate 29348-79-6, Pentanediol 77554-84-8, Sodium methyl glycine diacetate **78418-01-6**, 5-Octanoyl salicylic acid 96702-03-3, Ectoin 96702-03-3D, Ectoin, derivs. 100441-38-1 104365-75-5, Glyceryl polyacrylate 131334-66-2 311313-38-9, Vitamin E diphosphate 607717-55-5 607717-56-6
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Lvmh Rech; FR 2673840 A 1992 HCAPLUS
(2) Meybeck, A; US 5723149 A 1998 HCAPLUS
(3) Oreal; FR 2811561 A 2002 HCAPLUS
(4) Oreal; FR 2811567 A 2002 HCAPLUS
(5) Rubinstenn, G; US 6331535 B1 2001 HCAPLUS
(6) Rubinstenn, G; US 2002028186 A1 2002 HCAPLUS
IT **9004-61-9**, **Hyaluronic acid 9004-61-9D**, **Hyaluronic acid**, derivs. **78418-01-6**, 5-Octanoyl salicylic acid
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sapogenin or natural extract containing it for treatment of oligoseborrheic dry skin)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 78418-01-6 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxooctyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:397101 HCAPLUS
DN 138:403139
ED Entered STN: 23 May 2003
TI Application of hydrophilic coatings to biomedical articles
IN Chabrecek, Peter; Leukel, Joerg; Biedermann, Hynek; Lohmann, Dieter
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G02B001-04
ICS A61L027-34
CC 42-10 (Coatings, Inks, and Related Products)
Section cross-reference(s): 38, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003042724	A1	20030522	WO 2002-EP12658	20021112 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	CA 2467092	AA	20030522	CA 2002-2467092	20021112 <--
	US 2003219533	A1	20031127	US 2002-292836	20021112 <--
	US 6878399	B2	20050412		
	EP 1451615	A1	20040901	EP 2002-779553	20021112 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005512115	T2	20050428	JP 2003-544501	20021112 <--
PRAI	EP 2001-811088	A	20011113 <--		
	WO 2002-EP12658	W	20021112		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003042724	ICM	G02B001-04
	ICS	A61L027-34
WO 2003042724	ECLA	A61L027/34; A61L027/50; G02B001/04B2 <--
US 2003219533	NCL	427/162.000
	ECLA	A61L027/34; A61L027/50; G02B001/04B2 <--
JP 2005512115	FTERM	2H006/BB10; 2H006/BC05; 4C081/AB22; 4C081/AB23; 4C081/BA03; 4C081/BB01; 4C081/CA012; 4C081/CA082;

4C081/CA152; 4C081/CA181; 4C081/CA271; 4C081/CC01; 4C081/CC03; 4C081/CD082; 4C081/DA01; 4C081/DB07; 4C081/DC03; 4C081/EA02; 4C081/EA06; 4D075/CA37; 4D075/DB11; 4D075/DB31; 4D075/DC30; 4D075/EB22; 4D075/EB42; 4F006/AA42; 4F006/AB42; 4F006/BA10; 4F006/CA05 <--

AB The invention relates to a process for coating a material surface, comprising the steps of: (a) providing an inorg. or organic bulk material; (b) providing one or more polyionic materials at least one of them comprising covalently bound initiator moieties for radical polymerization; (c) applying the polyionic material of step (b) to the bulk material of step (a), thereby forming a hydrophilic layer on the bulk material surface; and (d) graft polymerizing a hydrophilic monomer or macromonomer onto said polyionic material. The coated articles that are obtainable by the process of the invention have desirable characteristics regarding adherence to the substrate, durability, hydrophilicity, wettability, biocompatibility and permeability and are thus useful for the manufacture of biomedical articles such as ophthalmic devices. Thus, diluting a 25% aqueous polyacrylic acid with 500 mL water, adding 1.9 g 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride dissolved in 5 mL water, 2.1 g N-hydroxysulfosuccinimide Na salt dissolved in 5 mL water, and 2.67 g 2-hydroxy-2-methyl-1-[4-[2-(2-hydroxyethylamino)ethoxy]phenyl]-1-propanone initiator, stirring at pH 9 overnight gave polyacrylic acid having pendant photoinitiator groups. Lotrafilcon A lenses (polysiloxane-perfluoroalkyl polyether copolymer) was immersed on a 0.001 M aqueous solution of the above-described polyacrylic acid having pendant photoinitiator groups for 5 min and directly immersed in a 0.001 M aqueous polyallylamine hydrochloride solution for 5 min. This treated lens was immersed in a solution of a product of 0.81 g isocyanatoethyl methacrylate and 7.5 g telomer prepared by reaction of 99.5 g acrylamide with 15.6 g cysteamine hydrochloride in the presence of 2,2'-azobisisobutyramidine hydrochloride and exposed to UV light for 2 min to give a lens with water-air contact angles 0, 0, 0° adv., rec., and hysteresis, resp., compared with 101, 64, and 37°, resp. for nonmodified lens.

ST graft polymer hydrophilic coating ophthalmic lens; acrylamide cysteamine telomer isocyanatoethyl methacrylate deriv hydrophilic coating lens; polyallylamine hydrochloride hydrophilic coating ophthalmic lens; polyacrylic acid ketone ester hydrophilic coating ophthalmic lens; polysiloxane perfluoropolyether lens hydrophilic coating

IT Intraocular lenses
(application of hydrophilic coatings to biomedical articles such as intraocular lenses)

IT Contact lenses
(application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT Eye
(artificial cornea; application of hydrophilic coatings to biomedical articles such as artificial corneas)

IT Polymerization
(graft, photochem.; in application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT Coating materials
(hydrophilic coatings; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT Polysiloxanes, uses
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polyether-, perfluoro, Lotrafilcon A, lenses; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT Fluoropolymers, uses
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polyether-polysiloxane-, Lotrafilcon A, lenses; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT Polyethers, uses
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polysiloxane-, perfluoro, Lotrafilcon A, lenses; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT 249758-93-8P 302352-91-6P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(coating component precursor; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT 530112-85-7P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(coating component; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT 9002-98-6DP, reaction products with hydroxy[(succimidooxycarbonylmethoxy)phenyl]methylpropanone **9004-61-9DP, Hyaluronic acid**, reaction products with **hydroxy[[(hydroxyethylamino)ethoxy]phenyl]methylpropanone** 30674-80-7DP, reaction products with acrylamide-cysteamine hydrochloride telomer 249758-93-8DP, reaction products with isocyanatoethyl methacrylate 302352-91-6DP, reaction products with isocyanatoethyl methacrylate 528870-63-5DP, reaction products with polyethyleneimine
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(coating component; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT 71550-12-4, Polyallylamine hydrochloride
RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coating component; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT 4098-71-9DP, Isophorone diisocyanate, reaction products with (hydroxyethoxy)phenylhydroxypropyl ketone and polyallylamine 30551-89-4DP, Polyallylamine, reaction products with (hydroxyethoxy)phenylhydroxypropyl ketone-isophorone diisocyanate 127770-74-5P, 2-Hydroxy-1-[4-(2-methanesulfonyloxyethoxy)phenyl]-2-methyl-1-propanone 528870-62-4P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(precursor; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

IT 124-63-0, Methanesulfonyl chloride **106797-53-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Ciba Geigy Ag; WO 9620796 A 1996 HCAPLUS
(2) Novartis Erfind Verwalt Gmbh; WO 9935520 A 1999 HCAPLUS
(3) Novartis Erfind Verwalt Gmbh; WO 9957581 A 1999 HCAPLUS
(4) Novartis Erfind Verwalt Gmbh; WO 0192924 A 2001 HCAPLUS
(5) Novartis Erfind Verwalt Gmbh; EP 1095711 A 2001 HCAPLUS
(6) Novartis Erfind Verwalt Gmbh; EP 1095966 A 2001 HCAPLUS
(7) Novartis Erfind Verwalt Gmbh; WO 02094331 A 2002 HCAPLUS

IT **9004-61-9DP, Hyaluronic acid**, reaction products with **hydroxy[[(hydroxyethylamino)ethoxy]phenyl]methylpropanone**
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(coating component; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **106797-53-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; application of hydrophilic coatings to biomedical articles such as ophthalmic lenses)
RN 106797-53-9 HCAPLUS
CN 1-Propanone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:905941 HCAPLUS
DN 137:389246
ED Entered STN: 29 Nov 2002
TI Bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses
IN Chabrecek, Peter; Leukel, Joerg; Lohmann, Dieter
PA Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61L027-34
CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 37
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094331	A1	20021128	WO 2002-EP5495	20020517 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	US 2003008063	A1	20030109	US 2002-142300	20020509 <--
	US 6835410	B2	20041228		
	EP 1395302	A1	20040310	EP 2002-727603	20020517 <--
	EP 1395302	B1	20050202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004536633	T2	20041209	JP 2002-591047	20020517 <--
	AT 288289	E	20050215	AT 2002-727603	20020517 <--
PRAI	EP 2001-810503	A	20010521 <--		
	WO 2002-EP5495	W	20020517		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002094331	ICM	A61L027-34
WO 2002094331	ECLA	A61L027/34 <--
US 2003008063	NCL	427/002.100

ECLA A61L027/34 <--
JP 2004536633 FTERM 4C081/AB22; 4C081/AB23; 4C081/BA03; 4C081/CA08;
4C097/AA25; 4C097/BB01; 4C097/CC03; 4C097/DD02;
4C097/EE01; 4D075/BB42Z; 4D075/BB46Z; 4D075/CA31;
4D075/CA37; 4D075/DA04; 4D075/DA06; 4D075/DA11;
4D075/DA15; 4D075/DA23; 4D075/DB01; 4D075/DB11;
4D075/DB13; 4D075/DB14; 4D075/DB20; 4D075/DB32;
4D075/DB35; 4D075/DB36; 4D075/DB37; 4D075/DB38;
4D075/DB39; 4D075/DB40; 4D075/DB43; 4D075/DB47;
4D075/DB48; 4D075/DB50; 4D075/DB53; 4D075/DB54;
4D075/DC24; 4D075/DC30; 4D075/EA07; 4D075/EA21;
4D075/EB07; 4D075/EB16; 4D075/EB19; 4D075/EB20;
4D075/EB22; 4D075/EB24; 4D075/EB33; 4D075/EB38;
4D075/EC07; 4D075/EC37; 4F073/AA01; 4F073/BA27;
4F073/BA33; 4F073/BA52; 4F073/BB02; 4F073/FA01;
4J038/CP001; 4J038/FA23; 4J038/NA06; 4J038/NA11;
4J038/NA12; 4J038/PA07; 4J038/PB08; 4J127/AA03;
4J127/AA06; 4J127/BB021; 4J127/BB041; 4J127/BB081;
4J127/BB101; 4J127/BB211; 4J127/BB221; 4J127/BC021;
4J127/BC031; 4J127/BC131; 4J127/BC141; 4J127/BC151;
4J127/BD061; 4J127/BE44X; 4J127/BE441; 4J127/BE51Y;
4J127/BE511; 4J127/BG30Y; 4J127/BG301; 4J127/DA38;
4J127/DA41; 4J127/DA46; 4J127/DA47; 4J127/EA12;
4J127/EA13; 4J127/EA21; 4J127/EA29; 4J127/FA07;
4J127/FA08; 4J127/FA25; 4J127/FA26; 4J127/FA43 <--

AB A process for coating a material surface comprises the steps of: (a) providing an inorg. or organic bulk material having covalently bound to its surface initiator moieties for radical polymerization; and (b) graft polymerizing a hydrophilic ethylenically unsatd. macromonomer from the bulk material surface in the presence of a biocompatible hydrophilic polymer being devoid of polymerizable ethylenically unsatd. groups and thereby entrapping said hydrophilic polymer within the polymer matrix formed by the polymerization of the macromonomer. Composite materials obtainable according to the process of the invention have desirable characteristics regarding adherence to the substrate, durability, hydrophilicity, wettability, biocompatibility and permeability and are thus useful for the manufacture of biomedical articles such as ophthalmic devices. Examples are given for photografting of Lotrafilcon A contact lenses with macromers and preparation of telomers.

ST macromer telomer prepn photografting contact intraocular lens; hydrophilic polymer biomedical coating

IT Eye
(artificial cornea; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

IT Contact lenses
Intraocular lenses
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

IT Macromonomers
Telomers (polymers)
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

IT Mucins
Polyoxyalkylenes, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

IT Prosthetic materials and Prosthetics
(composites, implants, ophthalmic; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

IT Polymerization
(graft, photochem.; bottle-brush type coatings with entangled

hydrophilic polymer for biomedical uses)
IT Coating process
(plasma spraying; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Polyoxyalkylenes, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyamine-; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Polysiloxanes, biological studies
RL: DEV (Device component use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(polyether-, perfluoro, functionalized, ethylenically unsatd. derivs., graft polymers; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Polysiloxanes, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyether-, perfluoro; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Fluoropolymers, biological studies
RL: DEV (Device component use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(polyether-polysiloxane-, functionalized, ethylenically unsatd. derivs., graft polymers; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Fluoropolymers, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyether-polysiloxane-; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Polyamines
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyoxyalkylene-; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Polyethers, biological studies
RL: DEV (Device component use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(polysiloxane-, perfluoro, functionalized, ethylenically unsatd. derivs., graft polymers; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Polyethers, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polysiloxane-, perfluoro; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT Coating process
(spray; bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)
IT 121-44-8DP, Triethylamine, IPDI-functionalized ketone alc. derivs., reaction products with polysiloxane polyethers, graft polymer derivs. 694-83-7DP, 1,2-Diaminocyclohexane, reaction products with polysiloxane polyethers, graft polymer derivs. 4098-71-9DP, reaction products with hydroxybutanones and polysiloxane polyethers, graft polymer derivs. 30674-80-7DP, reaction products with polysiloxane polyethers, graft polymer derivs. **106797-53-9DP**, Darocur 2959, IPDI-functionalized, reaction products with polysiloxane polyethers, graft polymer derivs. 180681-42-9DP, IPDI-functionalized, reaction products with polysiloxane polyethers, graft polymer derivs. 249758-93-8DP, isocyanatoethyl methacrylate-functionalized, photografting derivs. 249758-93-8P 302352-91-6DP, isocyanatoethyl methacrylate-functionalized, photografting derivs. 302352-91-6P 415900-81-1DP, reaction products

with polysiloxane polyethers, graft polymer derivs. 476337-31-2DP, IPDI-functionalized, reaction products with polysiloxane polyethers, graft polymer derivs.
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

IT 1398-61-4D, Chitin, carboxyalkyl derivs. 9002-89-5, Polyvinyl alcohol 9003-01-4D, Polyacrylic acid, crosslinked 9003-05-8, Polyacrylamide 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose 9004-54-0, Dextran, biological studies **9004-61-9**, **Hyaluronic acid** 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9012-76-4D, Chitosan, carboxyalkyl derivs. **9067-32-7**, Sodium **hyaluronate** 25322-68-3, Polyethylene glycol 33410-59-2, PolyHEMA 138757-68-3, Carbopol 981
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Ciba Geigy Ag; WO 9620919 A 1996 HCAPLUS
(2) Novartis Ag; WO 9957581 A 1999 HCAPLUS
(3) Novartis Erfind Verwalt Gmbh; EP 1095966 A 2001 HCAPLUS

IT **106797-53-9DP**, Darocur 2959, IPDI-functionalized, reaction products with polysiloxane polyethers, graft polymer derivs.
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

RN 106797-53-9 HCAPLUS
CN 1-Propanone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



IT **9004-61-9**, **Hyaluronic acid** 9067-32-7, Sodium **hyaluronate**
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bottle-brush type coatings with entangled hydrophilic polymer for biomedical uses)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9067-32-7 HCAPLUS
CN Hyaluronic acid, sodium salt (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L30 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:850724 HCAPLUS
DN 135:376535
ED Entered STN: 23 Nov 2001
TI Composition for make-up or skin-care in a powdery form containing a

particular binder
IN Hadasch, Anke; Lemann, Patricia; Simonnet, Jean-tierry
PA L'oreal, Fr.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K007-035
CC 62-4 (Essential Oils and Cosmetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1155676	A2	20011121	EP 2001-401249	20010515 <--
	EP 1155676	A3	20021218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2808999	A1	20011123	FR 2000-6448	20000519 <--
	FR 2808999	B1	20021031		
	JP 2002020236	A2	20020123	JP 2001-148415	20010517 <--
	CN 1331967	A	20020123	CN 2001-122173	20010518 <--
	US 2002041854	A1	20020411	US 2001-860567	20010521 <--
PRAI	FR 2000-6448	A	20000519 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 1155676	ICM	A61K007-035
EP 1155676	ECLA	A61K008/02H; A61K008/14; A61K008/34D; A61Q001/12 <--
FR 2808999	ECLA	A61K008/02H; A61K008/14; A61K008/34D; A61Q001/12 <--
US 2002041854	NCL	424/063.000
	ECLA	A61K008/02H; A61K008/14; A61K008/34D; A61Q001/12 <--

OS MARPAT 135:376535
AB A make-up composition contains a powdery phase and a binding phase which a continuous aqueous phase. A binding phase contained iso-Pr myristate 1.64, castor oil 2.46, vaseline oil 12.36, liquid lanolin 1.26, water 70.95, imidazolinyl urea 0.3, glycerin 5, Acylglutamate HS-11 0.03, phytantriol 2.97, vaseline 2.28, chlorphenesine 0.25, and polyoxyethylene sorbitan monopalmitate 0.5%. A cosmetic make-up contained talc 77.06, iron oxide 2.74, Nylon powder 10, titanium oxide 1, preservative 0.2, and above binding phase 9%.
ST makeup cosmetic powder particle binding phase
IT Amino acids, biological studies
Peptides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(N-acyl; composition for make-up or skin-care in powdery form containing particular binder)
IT Sulfonic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alkyl derivs.; composition for make-up or skin-care in powdery form containing particular binder)
IT Betaines
Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alkyl; composition for make-up or skin-care in powdery form containing particular binder)
IT Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; composition for make-up or skin-care in powdery form containing particular binder)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(animal; composition for make-up or skin-care in powdery form containing

particular binder)
IT Cosmetics
(antiaging; composition for make-up or skin-care in powdery form containing particular binder)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(avocado; composition for make-up or skin-care in powdery form containing particular binder)
IT Polyelectrolytes
(cationic; composition for make-up or skin-care in powdery form containing particular binder)
IT Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cetyl Me, di-Me; composition for make-up or skin-care in powdery form containing particular binder)
IT Aloe barbadensis
Alopecia
Anthraquinone dyes
Anti-inflammatory agents
Antibacterial agents
Azo dyes
Caramel (color)
Ceramics
Deodorants
Dyes
Fungicides
Gelation agents
Humectants
Insecticides
Microcapsules
Microspheres
Pearl
Pigments, nonbiological
Reducing agents
Sequestering agents
Stabilizing agents
Sunscreens
Suntanning agents
Surfactants
(composition for make-up or skin-care in powdery form containing particular binder)
IT Alcohols, biological studies
Carbon black, biological studies
Castor oil
Corn oil
Corticosteroids, biological studies
Cottonseed oil
Ethers, biological studies
Fatty acids, biological studies
Flavonoids
Fluoropolymers, biological studies
Glycerides, biological studies
Hydrocarbon oils
Isoalkanes
Jojoba oil
Kaolin, biological studies
Lactoferrins
Mica-group minerals, biological studies
Olive oil
Paraffin oils
Peanut oil
Peptides, biological studies
Phosphatidic acids
Polyamides, biological studies

Polyesters, biological studies
Polymers, biological studies
Polysiloxanes, biological studies
Polyurethanes, biological studies
Rape oil
Retinoids
Sapogenins
Soaps
Soybean oil
Sunflower oil
Tocopherols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(composition for make-up or skin-care in powdery form containing particular binder)

IT Amines, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(composition for makeup or skin care in powdery form containing particular binder)

IT Cosmetics
Hair preparations
(conditioners; composition for make-up or skin-care in powdery form containing particular binder)

IT Dyes
(direct; composition for make-up or skin-care in powdery form containing particular binder)

IT Hair preparations
(dyes, oxidative; composition for make-up or skin-care in powdery form containing particular binder)

IT Hair preparations
(dyes; composition for make-up or skin-care in powdery form containing particular binder)

IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(essential, glycerides; composition for make-up or skin-care in powdery form containing particular binder)

IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ethoxylated; composition for make-up or skin-care in powdery form containing particular binder)

IT Centella asiatica
(extract, composition for make-up or skin-care in powdery form containing particular binder)

IT Cosmetics
(eye liners; composition for make-up or skin-care in powdery form containing particular binder)

IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fatty; composition for make-up or skin-care in powdery form containing particular binder)

IT Cosmetics
(foundations; composition for make-up or skin-care in powdery form containing particular binder)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy; composition for make-up or skin-care in powdery form containing particular binder)

IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lipo; composition for make-up or skin-care in powdery form containing

particular binder)
IT Cosmetics
(lipsticks; composition for make-up or skin-care in powdery form containing particular binder)
IT Cosmetics
(makeups; composition for make-up or skin-care in powdery form containing particular binder)
IT Cosmetics
(mascaras; composition for make-up or skin-care in powdery form containing particular binder)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(mink; composition for make-up or skin-care in powdery form containing particular binder)
IT Sterols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(phyto; composition for make-up or skin-care in powdery form containing particular binder)
IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyhydric; composition for make-up or skin-care in powdery form containing particular binder)
IT Cosmetics
(powders; composition for make-up or skin-care in powdery form containing particular binder)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sesame; composition for make-up or skin-care in powdery form containing particular binder)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(turtle; composition for make-up or skin-care in powdery form containing particular binder)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(vegetable; composition for make-up or skin-care in powdery form containing particular binder)
IT Cosmetics
(wrinkle-preventing; composition for make-up or skin-care in powdery form containing particular binder)
IT 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin c, biological studies 52-90-4, Cysteine, biological studies 55-56-1, Chlorhexidine 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-88-5, Cholesterol, biological studies 58-08-2, Caffein, biological studies 58-55-9, Theophylline, biological studies 60-18-4D, Tyrosine, derivs. 60-23-1, Cysteamine 60-33-3, Linoleic acid, biological studies 68-11-1, Thioglycolic acid, biological studies 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 70-30-4, Hexachlorophene 79-14-1, Glycolic acid, biological studies 79-81-2, Retinol palmitate 81-13-0, Panthenol 91-53-2, Ethoxyquine 93-60-7, Methyl nicotinate 96-26-4, Dihydroxyacetone 107-46-0, Hexamethyldisiloxane 110-27-0, Isopropyl myristate 111-01-3, Squalane 112-80-1, Oleic acid, biological studies 112-85-6, Behenic acid 112-92-5, Stearyl alcohol 118-00-3, Guanosine, biological studies 120-72-9D, Indole, derivs. 123-95-5, Butylstearate 124-07-2D, Caprylic acid, glycerides 125-33-7, Hexamidine 127-47-9, Retinol acetate 137-66-6, Ascorbyl palmitate 141-94-6, Hexetidine 142-47-2D, Monosodium glutamate, acyl derivs. 142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 302-79-4, Retinoic acid 302-79-4D, Retinoic acid, derivs. 334-48-5D, Capric acid, glycerides 463-40-1,

Linolenic acid 464-92-6, Asiatic acid 471-34-1, Calcium carbonate, biological studies 497-76-7, Arbutin 501-30-4, Kojic acid 515-69-5, α-Bisabolol 540-97-6 541-02-6 544-63-8, Myristic acid, biological studies 546-93-0, Magnesium carbonate 556-67-2 616-91-1, N-Acetyl cysteine 1190-73-4, N-Acetyl cysteamine 1256-86-6, Cholesteryl sulfate 1306-06-5, Hydroxyapatite 1314-13-2, Zinc oxide, biological studies 1314-23-4, Zirconium oxide, biological studies 1332-37-2, Iron oxide, biological studies 1406-18-4, Vitamin e 2197-63-9, Dicetylphosphate 2915-57-3 3380-34-5, Triclosan 4358-16-1, Cholesteryl phosphate 6640-03-5, Dimyristylphosphate 7069-42-3, Retinol propionate 7235-40-7, β-Carotene 7440-39-3D, Barium, salts, biological studies 7440-67-7D, Zirconium, salts, biological studies 7440-70-2D, Calcium, salts, biological studies 7631-86-9, Silica, biological studies 7787-59-9, Bismuth oxychloride 9001-92-7, Protease 9002-84-0, Polytetrafluoroethylene 9002-88-4, Polyethylene 9003-27-4, Polyisobutene 9003-53-6, Polystyrene **9004-61-9, Hyaluronic acid** 9005-25-8, Starch, biological studies 9011-14-7, Polymethylmethacrylate 9016-00-6, Polydimethylsiloxane **9067-32-7**, Sodium **hyaluronate** 10043-11-5, Boron nitride, biological studies 11042-64-1, γ-Orizanol 11103-57-4, Vitamin a 11118-57-3, Chromium oxide 11129-18-3, Cerium oxide 12240-15-2, Ferric Blue 13463-67-7, Titanium oxide, biological studies 14807-96-6, Talc, biological studies 16690-92-9D, Disodium glutamate, acyl derivs. 17181-54-3, β-Glycerophosphate 19660-77-6, Chlorophyllin 20545-92-0, Pur-cellin 22766-83-2, 2-Octyldodecyl myristate 23597-82-2, Hexyl nicotinate 24937-14-2, Poly(β-alanine) 25513-34-2, Poly(β-alanine) 26545-51-7, Diethyl toluamide 26942-95-0, Glycerin triisostearate 29468-20-0, Pyridinethione 29806-73-3, 2-Ethyl-hexyl palmitate 30399-84-9, Isostearic acid 31807-55-3, Isododecane 31900-57-9, Polydimethylsiloxane 34316-64-8, Hexyl laurate 34362-27-1, 2-Hexyl decyl laurate 34513-50-3, Octyldodecanol 36653-82-4, Cetanol 37309-58-3, Polydecene 38304-91-5, Minoxidil 38517-23-6, Acylglutamate HS-11 42131-25-9, Isononyl isononanoate 56275-01-5 57568-20-4, 2-Octyldodecyl lactate 57654-76-9 60554-19-0 60908-77-2, Isohexadecane 68890-66-4, Octopirox 70424-62-3 70942-90-4, Glyceol 74563-64-7, Phytantriol **78418-03-8**, n-Dodecanoyl 5-salicylic acid 80208-78-2, Glycerol thioglycolate 81230-05-9, Diisostearyl malate 108910-78-7, Magnesium ascorbyl phosphate 120486-24-0, Diglycerin triisostearate 127278-53-9 134112-33-7, 2-Octyl decyl palmitate 145278-13-3 156218-15-4 197912-25-7 200260-57-7 374538-88-2D, derivs. 374690-63-8
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(composition for make-up or skin-care in powdery form containing particular binder)

IT 7440-32-6, Titanium, biological studies 7440-66-6, Zinc, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(nano-; composition for make-up or skin-care in powdery form containing particular binder)

IT **9004-61-9, Hyaluronic acid 9067-32-7**, Sodium **hyaluronate 78418-03-8**, n-Dodecanoyl 5-salicylic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(composition for make-up or skin-care in powdery form containing particular binder)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9067-32-7 HCAPLUS
CN Hyaluronic acid, sodium salt (9CI) (CA INDEX NAME)

Search done by Noble Jarrell

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 78418-03-8 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxododecyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:505749 HCAPLUS
DN 131:134425
ED Entered STN: 16 Aug 1999
TI Cleaning patch for improving the skin condition
IN Gueret, Jean-Louis
PA L'Oreal, Fr.
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K007-00
ICS A61K007-50
CC 62-4 (Essential Oils and Cosmetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 933077	A1	19990804	EP 1998-403340	19981230	<--
	EP 933077	B1	20030212			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	FR 2774287	A1	19990806	FR 1998-1070	19980130	<--
	FR 2774287	B1	20000512			
	AT 232378	E	20030215	AT 1998-403340	19981230	<--
	ES 2192314	T3	20031001	ES 1998-403340	19981230	<--
	CA 2257493	AA	19990730	CA 1999-2257493	19990119	<--
	JP 11269032	A2	19991005	JP 1999-14767	19990122	<--
	MX 9900968	A	20000831	MX 1999-968	19990126	<--
	CN 1227095	A	19990901	CN 1999-101713	19990129	<--
PRAI	FR 1998-1070	A	19980130	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
EP 933077	ICM	A61K007-00	
	ICS	A61K007-50	
EP 933077	ECLA	A61K008/02C; A61Q019/10	<--
FR 2774287	ECLA	A61K008/02C; A61Q019/10	<--
AT 232378	ECLA	A61K008/02C; A61Q019/10	<--
ES 2192314	ECLA	A61K008/02C; A61Q019/10	<--
CA 2257493	ECLA	A61K008/02C; A61Q019/10	<--
JP 11269032	ECLA	A61K008/02C; A61Q019/10	<--
CN 1227095	ECLA	A61K008/02C; A61Q019/10	<--

AB A cleaning patch for improving skin conditions comprises a polymeric matrix which contains an active ingredient. A skin patch contained acrylic polymer in Et acetate 69.5%, Blue de Prusse pigment 0.5, urea 20, and salicylic acid 10%. The patch is used for the treatment of acne.
ST cleaning patch skin disease acrylic polymer; salicylic acid urea acne skin patch
IT Vinyl compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)
(carboxy-containing, polymers; cleaning patch for improving skin condition)
IT Antibiotics
Centella asiatica
Cotton fibers
Honey
Pigments, nonbiological
Yeast
(cleaning patch for improving skin condition)
IT Acrylic polymers, biological studies
Amino acids, biological studies
Carbon black, biological studies
Caseins, biological studies
Ceramides
Enzymes, biological studies
Gelatins, biological studies
Jojoba oil
Kaolin, biological studies
Mucopolysaccharides, biological studies
Phospholipids, biological studies
Polyamides, biological studies
Polypropene fibers, biological studies
Polysiloxanes, biological studies
Polyurethanes, biological studies
Proteins, general, biological studies
Salts, biological studies
Sphingomyelins
Tannins
Waxes
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cleaning patch for improving skin condition)
IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(essential; cleaning patch for improving skin condition)
IT Polyolefin fibers
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ethylene; cleaning patch for improving skin condition)
IT Melissa
Microalgae
Rosemary
(extract; cleaning patch for improving skin condition)
IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy, esters; cleaning patch for improving skin condition)
IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy; cleaning patch for improving skin condition)
IT Peptides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oligopeptides; cleaning patch for improving skin condition)
IT Colloids
(phycocolloids; cleaning patch for improving skin condition)
IT Vinyl compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polymers; cleaning patch for improving skin condition)
IT Anti-inflammatory agents
(steroidal; cleaning patch for improving skin condition)
IT Plastics, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)
(thermoplastics; cleaning patch for improving skin condition)
IT 50-14-6, Vitamin d2 50-21-5, biological studies 50-78-2, Acetyl salicylic acid 50-81-7, L-Ascorbic acid, biological studies 57-13-6, Urea, biological studies 57-50-1, Sucrose, biological studies 58-85-5, Vitamin h 59-02-9, D-α-Tocopherol 59-30-3, Folic acid, biological studies 67-97-0, Vitamin d3 68-26-8, Retinol 68-26-8D, Retinol, esters 69-72-7, biological studies 77-92-9, biological studies 79-14-1, biological studies 79-81-2, Retinol palmitate 83-88-5, Vitamin b2, biological studies 87-69-4, biological studies 90-64-2, Mandelic acid 97-59-6, Allantoin 117-39-5, Quercetin 123-31-9, 1,4-Benzenediol, biological studies 137-66-6, Ascorbyl palmitate 464-92-6, Asiatic acid 471-53-4, Glycyrrhetic acid 501-30-4, Kojic acid 515-69-5, α-Bisabolol 1309-37-1, Iron oxide (Fe2O3), biological studies 1314-13-2, Zinc oxide, biological studies 1314-23-4, Zirconium oxide, biological studies 1332-37-2, Iron oxide, biological studies 1406-16-2, Vitamin d 1449-05-4, β-Glycyrrhetinic acid 4602-84-0, Farnesol 5281-04-9, Dc red # 7 6915-15-7, Malic acid 7069-42-3, Retinol propionate 7235-40-7, β Carotene 8059-24-3, Vitamin b6 9000-01-5, Gum arabic 9000-30-0, Guar gum 9000-65-1, Gum tragacanth 9002-86-2, Polyvinyl chloride 9002-88-4, Polyethylene 9003-07-0, Polypropylene 9004-34-6D, Cellulose, semi-synthetic derivs., biological studies **9004-61-9**, **Hyaluronic acid** 9005-25-8, Starch, biological studies 10191-41-0, DL-α-Tocopherol 11032-50-1, Vitamin pp 11118-57-3, Chromium oxide 11129-18-3, Cerium oxide 13463-67-7, Titanium oxide, biological studies 16830-15-2, Asiaticoside 18449-41-7, Madecassic acid 24937-78-8, Ethylene vinyl acetate copolymer 29548-30-9, Farnesyl acetate 52225-20-4, DL-α-Tocopherol acetate 74563-64-7, Phytanetriol **78418-01-6**, n-Octanoyl-5-salicylic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cleaning patch for improving skin condition)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Lavipharm; FR 2750050 A 1997 HCAPLUS
(2) The Procter And Gamble Co; WO 9402674 A 1994
IT **9004-61-9**, **Hyaluronic acid 78418-01-6**
, n-Octanoyl-5-salicylic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cleaning patch for improving skin condition)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 78418-01-6 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxooctyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:337097 HCAPLUS
DN 131:23323
ED Entered STN: 02 Jun 1999
TI Norlignans with hyaluronidase inhibitory activity from Anemarrhena

asphodeloides
AU Jeong, Sei-Joon; Ahn, Nyeon-Hyoung; Kim, Youn-Chul; Inagaki, M.; Miyamoto, T.; Higuchi, R.
CS College Pharmacy, Wonkwang Univ., Iksan, 570749, S. Korea
SO Planta Medica (**1999**), 65(4), 367-368
CODEN: PLMEAA; ISSN: 0032-0943
PB Georg Thieme Verlag
DT Journal
LA English
CC 63-4 (Pharmaceuticals)
Section cross-reference(s): 7, 11
AB Assay-guided fractionation of an MeOH extract of Anemarrhena asphodeloides furnished hyaluronidase inhibitory norlignans cis-hinokiresinol and 1,3-bis(4-hydroxyphenyl)-4-penten-1-one and inactive 4'-methyl-cis-hinokiresinol.
ST norlignan hyaluronidase inhibitor Anemarrhena
IT Anemarrhena asphodeloides
New natural products
(norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides)
IT Lignans
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides)
IT 79004-25-4 96895-25-9, cis-Hinokiresinol **226417-45-4**
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides)
IT **37326-33-3**, E.C. 3.2.1.35
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Cox, J; Nature 1967, V216, P1328 HCAPLUS
(2) Jeong, S; Kor J Pharmacogn 1997, V28, P131
(3) Kakegawa, H; Chem Pharm Bull 1985, V33, P642 HCAPLUS
(4) Koda, A; J Allergy Clin Immunol 1976, V57, P396 HCAPLUS
(5) Tang, W; Chinese Drugs of Plant Origin 1992, P105
(6) Tsui, W; Phytochemistry 1996, V43, P1413 HCAPLUS
(7) Tung, J; Anal Biochem 1994, V223, P149 HCAPLUS
IT **226417-45-4**
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides)
RN 226417-45-4 HCAPLUS
CN 4-Penten-1-one, 1,3-bis(4-hydroxyphenyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



Search done by Noble Jarrell

IT 37326-33-3, E.C. 3.2.1.35
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(norlignans with hyaluronidase inhibitory activity from Anemarrhena asphodeloides)
RN 37326-33-3 HCAPLUS
CN Hyaluronoglucosaminidase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L30 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:700961 HCAPLUS
DN 130:7409
ED Entered STN: 04 Nov 1998
TI Transdermal patches for drug delivery
IN Gueret, Jean-Louis H.
PA L'Oreal S. A., Fr.
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K009-70
ICS A61K009-70
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	JP 10287559	A2	19981027	JP 1998-93612	19980406	<--
	JP 2865659	B2	19990308			
	FR 2761889	A1	19981016	FR 1997-4498	19970411	<--
	FR 2761889	B1	19991231			
	EP 870498	A1	19981014	EP 1998-400647	19980319	<--
	EP 870498	B1	20050511			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO					
	MX 9802825	A	20000731	MX 1998-2825	19980408	<--
	CA 2232616	AA	19981011	CA 1998-2232616	19980409	<--
	CA 2232616	C	20040622			
	US 6280765	B1	20010828	US 1998-58883	19980413	<--
PRAI	FR 1997-4498	A	19970411	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
JP 10287559	ICM	A61K009-70	
	ICS	A61K009-70	
FR 2761889	ECLA	A61K007/48Z2B; A61K009/70E	<--
EP 870498	ECLA	A61K008/02C; A61K009/70E	<--
US 6280765	NCL	424/449.000; 424/400.000; 424/402.000; 424/443.000; 424/445.000; 424/447.000	
	ECLA	A61K007/48Z2B; A61K009/70E	<--

AB Patches which deliver lipid-soluble drugs and water-soluble drugs at the same time, comprise hydrophobic polymers containing the active agents, water absorbents, and oils. A mixture containing sweet almond oils (containing trans-retinol), microcryst. vitamin C, polyacrylic acid powder, and organopolysiloxane (DC 3.6486) was cured and the mixture was applied on a polyethylene sheet to a thickness of 0.8 mm. The sheet was assembled with self-adhesive silicone matrix to give a transdermal patch.
ST transdermal patch water sol insol drug delivery; ascorbate retinol polyacrylate polyethylene sheet patch
IT Vinyl compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carboxy-containing, polymers; transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT Centella asiatica
Rosemary

(exts.; transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT Anti-inflammatory agents
(steroidal; transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT Drug delivery systems
(tapes; transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT Cotton fibers
(transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT Amino acids, biological studies
Balsams
Caseins, biological studies
Glycerides, biological studies
Mucopolysaccharides, biological studies
Peptides, biological studies
Phospholipids, biological studies
Polyesters, biological studies
Polysiloxanes, biological studies
Polyurethanes, biological studies
Protein hydrolyzates
Silicone rubber, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT 50-14-6, Vitamin D2 50-21-5D, Lactic acid, esters 50-78-2, Acetylsalicylic acid 57-13-6, Urea, biological studies 58-95-7, D-α-Tocopherol acetate 59-02-9, D-α-Tocopherol 67-97-0, Vitamin D3 68-26-8, Retinol 69-72-7D, Salicylic acid, esters 77-92-9, Citric acid, biological studies 79-14-1D, Glycolic acid, esters 79-81-2, Retinyl palmitate 81-13-0, D-Panthenol 83-88-5, Riboflavin, biological studies 91-53-2, Ethoxyquin 97-59-6, Allantoin 117-39-5, Quercetin 123-31-9, 1,4-Benzenediol, biological studies 137-66-6, Ascorbyl palmitate 464-92-6, Asiatic acid 471-53-4 501-30-4, Kojic acid 515-69-5, α-Bisabolol 1406-16-2, Vitamin D 4602-84-0, Farnesol 7069-42-3, Retinyl propionate 7235-40-7, β-Carotene 8059-24-3, Vitamin B6 9000-01-5, Arabic gum 9000-30-0, Guar gum 9000-65-1, Tragacanth gum 9002-86-2, Polyvinyl chloride 9002-88-4 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-07-0 9004-34-6, Cellulose, biological studies **9004-61-9**, **Hyaluronic acid** 9005-25-8, Starch, biological studies 9016-00-6, Dimethylsilanediol polymer sru 10191-41-0, DL-α-Tocopherol 16830-15-2, Asiaticoside 18449-41-7, Madecassic acid 24937-78-8, Ethylene-vinyl acetate copolymer 29548-30-9, Farnesyl acetate 31900-57-9, Dimethylsilanediol polymer 52225-20-4, DL-α-Tocopheryl acetate 74563-64-7, Phytantriol **78418-01-6**
, 5-Octanoyl salicylic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
IT **9004-61-9**, **Hyaluronic acid 78418-01-6**
, 5-Octanoyl salicylic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal patches containing both lipid-soluble compds. and water-soluble compds. on hydrophobic polymeric layer)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 78418-01-6 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxooctyl)- (9CI) (CA INDEX NAME)



L30 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:551335 HCAPLUS
DN 125:171106
ED Entered STN: 17 Sep 1996
TI Functionalization of surfaces by coating and products therefrom
IN Chabrecek, Peter; Lohmann, Dieter
PA Ciba-Geigy A.-G., Switz.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM B05D003-14
ICS B05D003-06; G02B001-04
CC 42-10 (Coatings, Inks, and Related Products)
Section cross-reference(s): 63
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9620796	A1	19960711	WO 1995-EP5013	19951218	<--
	W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	CA 2208710	AA	19960711	CA 1995-2208710	19951218	<--
	AU 9643874	A1	19960724	AU 1996-43874	19951218	<--
	AU 698098	B2	19981022			
	BR 9510292	A	19971111	BR 1995-10292	19951218	<--
	EP 808222	A1	19971126	EP 1995-942693	19951218	<--
	EP 808222	B1	19990519			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE					
	CN 1174525	A	19980225	CN 1995-197514	19951218	<--
	JP 10511600	T2	19981110	JP 1995-520702	19951218	<--
	AT 180185	E	19990615	AT 1995-942693	19951218	<--
	ES 2134514	T3	19991001	ES 1995-942693	19951218	<--
	ZA 9511003	A	19960701	ZA 1995-11003	19951228	<--
	FI 9702699	A	19970822	FI 1997-2699	19970623	<--
	NO 9703022	A	19970825	NO 1997-3022	19970627	<--
PRAI	CH 1994-3967	A	19941230	<--		
	WO 1995-EP5013	W	19951218	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9620796	ICM	B05D003-14
	ICS	B05D003-06; G02B001-04
WO 9620796	ECLA	C07C271/20; C07C271/24; C07C271/28; C08F002/50; C08F283/12D; C08F290/02; C08F290/04A; C08G018/50C6; C08G018/50F2; C08G018/61; C08G018/64F9; C08G018/70; C08G018/80; C08G018/80H4; C08G018/81K3B4; C08G018/81K3B2; C08G077/442; G02B001/04B2; G02B001/04B2+C08L51/08S; G03F007/027; G03F007/031; G03F007/075M <--

AB The coating process comprises the use of a functional photoinitiator based

on an aminoacetophenone and a diisocyanate, or a macroinitiator derived therefrom, in a cascade of process steps. Coated films and contact lenses with good wettability are obtained. Thus, 2-ethyl-2-(dimethylamino)-1-[4-(2-hydroxyethoxy)phenyl]-4-penten-1-one was treated with IPDI to give a monoisocyanate product (I). I was used to treat a polybutadiene surface under UV irradiation and the surface was then treated with Jeffamine M 2070. The treated surface had advancing and retreating contact angles 66 and 47°, resp., compared to 102 and 78° for the corresponding angles for the untreated polymer.

ST functionalized coating wetting lens film; contact lens coating wetting improvement; macroinitiator aminoacetophenone diisocyanate product

IT Coating materials
(functionalization of coatings with macroinitiators)

IT Siloxanes and Silicones, preparation
RL: IMF (Industrial manufacture); PREP (Preparation)
(aminoalkyl, Petrarch PS 813, reaction products, with aminoacetophenone isocyanate derivs.; functionalization of coatings with macroinitiators)

IT Lenses
(contact, functionalization of coatings with macroinitiators)

IT Siloxanes and Silicones, preparation
RL: IMF (Industrial manufacture); PREP (Preparation)
(di-Me, gluconamidopropyl Me, reaction products with aminoacetophenone isocyanate derivs.; functionalization of coatings with macroinitiators)

IT Siloxanes and Silicones, preparation
RL: IMF (Industrial manufacture); PREP (Preparation)
(di-Me, aminopropyl group-terminated, reaction products, with aminoacetophenone isocyanate derivs.; functionalization of coatings with macroinitiators)

IT Siloxanes and Silicones, preparation
RL: IMF (Industrial manufacture); PREP (Preparation)
(hydrogen, reaction products, with aminoacetophenone isocyanate derivs.; functionalization of coatings with macroinitiators)

IT Monomers
RL: IMF (Industrial manufacture); PREP (Preparation)
(macro-, functionalization of coatings with macroinitiators)

IT Crosslinking catalysts
Polymerization catalysts
(photochem., functionalization of coatings with macroinitiators)

IT Collagens, preparation
RL: IMF (Industrial manufacture); PREP (Preparation)
(reaction products, with aminoacetophenone isocyanate derivs.; functionalization of coatings with macroinitiators)

IT Siloxanes and Silicones, uses
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(vinyl group-containing, reaction products, with aminoacetophenone isocyanate derivs.; functionalization of coatings with macroinitiators)

IT 9002-98-6DP, Aziridine homopolymer, reaction products with aminoacetophenone isocyanate derivs.
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(functionalization of coatings with macroinitiators)

IT 7585-39-9DP, β-Cyclodextrin, reaction products with aminoacetophenone isocyanate derivs. 9002-89-5DP, Poly(vinyl alcohol), reaction products with aminoacetophenone isocyanate derivs. 9003-17-2DP, Polybutadiene, reaction products with aminoacetophenone isocyanate derivs. 9004-54-0DP, Dextran, reaction products with aminoacetophenone isocyanate derivs. **9004-61-9DP, Hyaluronic acid**, reaction products with aminoacetophenone isocyanate derivs. 9046-10-0DP, Jeffamine D 2000, reaction products with aminoacetophenone isocyanate derivs. 39423-51-3DP, Jeffamine T 403, reaction products with aminoacetophenone isocyanate derivs. 65605-36-9DP, Jeffamine ED 2001, reaction products with aminoacetophenone isocyanate derivs. 83713-01-3DP, Jeffamine M 2070, reaction products with aminoacetophenone isocyanate derivs. 97917-34-5DP, X-22-161B, reaction products with aminoacetophenone isocyanate derivs. 163073-16-3DP, reaction products

with polymers 163073-17-4P 163073-19-6P 180681-41-8DP, reaction products with polymers 180681-44-1P 180681-45-2DP, reaction products with polymers 180681-46-3DP, reaction products with polymers 180838-99-7P 180839-07-0DP, reaction products with polymers 180839-09-2P
RL: IMF (Industrial manufacture); PREP (Preparation)
(functionalization of coatings with macroinitiators)
IT 163073-16-3P 180681-41-8P 180681-42-9P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(functionalization of coatings with macroinitiators)
IT 180681-72-5 180839-10-5
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(functionalization of coatings with macroinitiators)
IT 119312-38-8 180681-43-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(functionalization of coatings with macroinitiators)
IT 584-84-9 4098-71-9 16938-22-0, 2,2,4-Trimethylhexamethylene diisocyanate **106797-53-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; functionalization of coatings with macroinitiators)
IT **9004-61-9DP**, **Hyaluronic acid**, reaction products with aminoacetophenone isocyanate derivs.
RL: IMF (Industrial manufacture); PREP (Preparation)
(functionalization of coatings with macroinitiators)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **106797-53-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; functionalization of coatings with macroinitiators)
RN 106797-53-9 HCAPLUS
CN 1-Propanone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



L30 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:721436 HCAPLUS
DN 123:122734
ED Entered STN: 05 Aug 1995
TI Depigmentation composition for the simultaneous treatment of the superficial and deep skin layers
IN Ribier, Alain; Simonnet, Jean-Thierry; Fanchon, Chantal; Arnaud-Sebillotte, Laurence; Segot, Evelyne
PA Oreal S. A., Fr.
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K007-00
CC 62-3 (Essential Oils and Cosmetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 661038	A1	19950705	EP 1994-402980	19941221 <--

EP 661038	B1	19960724			
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
FR 2714601	A1	19950707	FR 1993-15870	19931230	<--
FR 2714601	B1	19960209			
AT 140612	E	19960815	AT 1994-402980	19941221	<--
ES 2092876	T3	19961201	ES 1994-402980	19941221	<--
CA 2138875	AA	19950701	CA 1994-2138875	19941222	<--
JP 07324029	A2	19951212	JP 1994-326418	19941227	<--
BR 9405484	A	19950919	BR 1994-5484	19941229	<--
HU 71380	A2	19951128	HU 1994-3828	19941229	<--
CN 1114558	A	19960110	CN 1994-120479	19941229	<--
CN 1051919	B	20000503			
RU 2105540	C1	19980227	RU 1994-45127	19941229	<--
US 5607692	A	19970304	US 1994-366739	19941230	<--
PRAI FR 1993-15870	A	19931230 <--			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 661038	ICM	A61K007-00
EP 661038	ECLA	A61K007/00M4D; A61K008/14; A61K008/34; A61K008/34F; A61K008/365; A61K008/368; A61K008/37; A61K008/42; A61K008/44; A61K008/49C4; A61K008/49H; A61K008/60; A61K008/67C; A61K008/67H; A61K008/73F; A61K008/73L; A61K008/97; A61K008/98F; A61Q019/02 <--
FR 2714601	ECLA	A61K007/00M4D; A61K008/14; A61K008/34; A61K008/34F; A61K008/365; A61K008/368; A61K008/37; A61K008/42; A61K008/44; A61K008/49C4; A61K008/49H; A61K008/60; A61K008/67C; A61K008/67H; A61K008/73F; A61K008/73L; A61K008/97; A61K008/98F; A61Q019/02 <--
US 5607692	NCL	424/450.000; 424/062.000; 424/401.000; 514/844.000
	ECLA	A61K007/00M4D; A61K008/14; A61K008/34; A61K008/34F; A61K008/365; A61K008/368; A61K008/37; A61K008/42; A61K008/44; A61K008/49C4; A61K008/49H; A61K008/60; A61K008/67C; A61K008/67H; A61K008/73F; A61K008/73L; A61K008/97; A61K008/98F; A61Q019/02 <--

AB Depigmentation compns. comprising dispersion of lipid vesicles for the simultaneous penetration into the superficial and the deep skin layers are claimed. Double liposome creams contained 31.3 g of vesicles for the deep layer (epidermis) comprising triglyceryl cetyl ether 7.6, cholesterol 7.6, sodium acylglutamate 0.8, kojic acid 2.0, glycerol 12.0, preservatives 0.1, and water q.s. 100 g; 25.0 g of vesicles for superficial layer (stratum corneum) comprising Chimexan NS:dimyristylphosphate (95:5) 20.00, N-octanoyl-5-salicylic acid 2.0, glycerol 15.0, preservatives 0.2, and water q.s. 100 g; and vegetable oils 4.5, preservatives 0.3, carboxyvinyl polymer 0.9, NaOH 1.8, and water q.s. 100%.

ST cosmetic dispersion lipid vesicle skin layer; depigmentation cosmetic dispersion liposome cream

IT Pigments
(depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Fatty acids, biological studies
Glycerides, biological studies
Inflammation inhibitors
Lipids, biological studies
Phospholipids, biological studies
Sunscreens
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Keratosis
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitors; depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Cosmetics

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(carboxy, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Skin, disease
(depigmentation, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Glycerides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(egg yolk, hydrogenated, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Skin
(epidermis, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Phospholipids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydrogenated, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Steroids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy, ethoxylated, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lipo, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Cosmetics
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(liposomes, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Cosmetics
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(moisturizers, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyhydric, alkyl ethers; depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(soya, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Skin

(stratum corneum, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sunflower-oil, depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT 16177-21-2, Sodium glutamate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(acyl; depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT 50-81-7, L-Ascorbic acid, biological studies 50-99-7, Glucose, biological studies 57-13-6, Urea, biological studies 57-88-5, Cholesterol, biological studies 69-72-7, biological studies 108-46-3, 1,3-Benzenediol, biological studies 123-31-9, 1,4-Benzenediol, biological studies 302-79-4, Retinoic acid 331-39-5 501-30-4, Kojic acid 2197-63-9, Dicetylphosphate 6640-03-5, Dimyristyl phosphate **9004-61-9, Hyaluronic acid** 9004-99-3, Polyethylene glycol stearate 9005-25-8, Starch, biological studies 25168-73-4, Saccharose stearate 25618-55-7D, Polyglycerol, C16-18-glycol derivs., lauryl ethers 26266-57-9, Sorbitan palmitate 27195-16-0, Saccharose distearate 51827-83-9 56090-54-1D, Triglycerol, hexadecyl ethers 63119-59-5, Diglycerol distearate 74563-64-7, Phytanetriol **78418-01-6**, Octanoyl-5-salicylic acid 99734-29-9, Tetraglyceryl tristearate 119831-19-5 128895-87-4, Triglycerol monohexadecyl ether 143747-72-2, Triglycerol, diether with 1-hexadecanol 166050-05-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT 9002-10-2, Tyrosinase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitors; depigmentation composition for simultaneous treatment of superficial and deep skin layers)

IT **9004-61-9, Hyaluronic acid 78418-01-6**
, Octanoyl-5-salicylic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(depigmentation composition for simultaneous treatment of superficial and deep skin layers)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 78418-01-6 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-(1-oxooctyl)- (9CI) (CA INDEX NAME)



=> b home
FILE 'HOME' ENTERED AT 14:10:10 ON 27 AUG 2005

=>